<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genomics</journal-id><journal-title>BMC Genomics</journal-title><issn pub-type="epub">1471-2164</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2164-8-455</article-id><article-id pub-id-type="pmid">18070348</article-id><article-id pub-id-type="doi">10.1186/1471-2164-8-455</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Gene expression and biological processes influenced by deletion of <italic>Stat3 </italic>in pulmonary type II epithelial cells</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Xu</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yan.xu@cchmc.org</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Ikegami</surname><given-names>Machiko</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>machiko.ikegami@cchmc.org</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Wang</surname><given-names>Yanhua</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yanhua.wang@cchmc.org</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Matsuzaki</surname><given-names>Yohei</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yohei.matsuzaki@cchmc.org</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Whitsett</surname><given-names>Jeffrey A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jeff.whitsett@cchmc.org</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH, USA</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>10</day><month>12</month><year>2007</year></pub-date><volume>8</volume><fpage>455</fpage><lpage>455</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2164/8/455"/><history><date date-type="received"><day>8</day><month>5</month><year>2007</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Xu et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Xu et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Xu Yan yan.xu@cchmc.org </dc:author><dc:title> Gene expression and biological processes influenced by deletion of Stat3 in pulmonary type II epithelial cells </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Genomics 8(1): 455-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2164(2007)8:1&#x0003c;455&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2164</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The signal transducer and activator of transcription 3 (STAT3) mediates gene expression in response to numerous growth factors and cytokines, playing an important role in many cellular processes. To better understand the molecular mechanisms by which <italic>Stat3 </italic>influences gene expression in the lung, the effect of pulmonary epithelial cell specific deletion of <italic>Stat3 </italic>on genome wide mRNA expression profiling was assessed. Differentially expressed genes were identified from Affymetrix Murine GeneChips analysis and subjected to gene ontology classification, promoter analysis, pathway mapping and literature mining.</p></sec><sec><title>Results</title><p>Total of 791 mRNAs were significantly increased and 314 mRNAs were decreased in response to the deletion of <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>in the lung. STAT is the most enriched cis-elements in the promoter regions of those differentially expressed genes. Deletion of <italic>Stat3 </italic>induced genes influencing protein metabolism, transport, chemotaxis and apoptosis and decreased the expression of genes mediating lipid synthesis and metabolism. Expression of <italic>Srebf1 </italic>and <italic>2</italic>, genes encoding key regulators of fatty acid and steroid biosynthesis, was decreased in type II cells from the <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice, consistent with the observation that lung surfactant phospholipids content was decreased. <italic>Stat3 </italic>influenced both pro- and anti-apoptotic pathways that determine cell death or survival. <italic>Akt</italic>, a potential transcriptional target of <italic>Stat3</italic>, was identified as an important participant in <italic>Stat3 </italic>mediated pathways including Jak-Stat signaling, apoptosis, Mapk signaling, cholesterol and fatty acid biosynthesis.</p></sec><sec><title>Conclusion</title><p>Deletion of <italic>Stat3 </italic>from type II epithelial cells altered the expression of genes regulating diverse cellular processes, including cell growth, apoptosis and lipid metabolism. Pathway analysis indicates that STAT3 regulates cellular homeostasis through a complex regulatory network that likely enhances alveolar epithelial cell survival and surfactant/lipid synthesis, necessary for the protection of the lung during injury.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The signal transducers and activators of transcription (STATs) were initially identified as a family of latent cytoplasmic transcription factors that are activated by various cytokines, growth factors and other stimuli, and phosphorylated by many protein kinases [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. In response to various stimuli, STAT family members are phosphorylated by receptor associated kinases, form homo- or heterodimers and are translocated to the cell nucleus where they activate transcription [<xref ref-type="bibr" rid="B5">5</xref>]. Recent studies also support the role of unphosphorylated STAT3 that accumulates in nucleus and activates transcription by binding to NFkappaB [<xref ref-type="bibr" rid="B6">6</xref>]. STAT3 regulates a variety of biological processes, functioning at both transcriptional and non-transcriptional levels to influence cell growth, survival and metabolism. Its capacity to induce cell transformation and tumorigenesis makes it a potential therapeutic target for various cancers [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Systemic deletion of <italic>Stat3 </italic>is embryonic lethal in the mouse, indicating its important role in embryogenesis [<xref ref-type="bibr" rid="B9">9</xref>]. Biological roles of STAT3 in various organs and cells have been studied <italic>in vitro </italic>as well as cell specific deletion in the mouse <italic>in vivo</italic>. The biological consequences of <italic>Stat3 </italic>deletion are surprisingly diverse and sometimes contradictory. For example, cardiomyocyte-specific STAT3 deficiency caused cardiac fibrosis and heart dysfunction with advanced age [<xref ref-type="bibr" rid="B10">10</xref>]. Hepatic cell specific deletion of <italic>Stat3 </italic>caused insulin resistance associated with increased expression of gluconeogenic genes [<xref ref-type="bibr" rid="B11">11</xref>]. Conditional ablation of <italic>Stat3 </italic>in respiratory epithelium of the mouse (<italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice) did not alter lung morphogenesis or function but enhanced susceptibility to hyperoxia and adenoviral induced lung injury whereas overexpression of Stat3C (a constitutive active form of STAT3) in pulmonary epithelium protects against hyperoxic lung injury, suggesting that STAT3 is required for the maintenance of surfactant homeostasis and lung function during injury [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. While STAT3 has been proposed as an anti-apoptotic protein through the induction of survival genes such as Bcl2-like 1(<italic>Bcl-X) and </italic>B-cell leukemia/lymphoma 2 <italic>(Bcl-2)</italic>, STAT3 also exerts pro-apoptotic effect through the regulation of insulin-like growth factor binding protein 5 (IGFBP-5) to modulate mammary epithelial apoptosis [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. STAT3 is abundantly and ubiquitously expressed in many tissues and distributed between the cell cytosol and nucleus. A direct effect of non-phosphorylated, cytoplasmic STAT3 on cell motility was reported recently through direct protein-protein interactions [<xref ref-type="bibr" rid="B16">16</xref>], indicating a non-transcriptional function of STAT3.</p><p>The functions of STAT3 vary in different cellular and physiologic contexts, influencing diverse gene targets by interaction with other proteins and genes. The diversity of STAT3 functions indicate that STAT3 is involved in complex genetic networks to maintain cellular homeostasis rather serving a singular role in acute phase responses as initially defined. In the present study, we sought to systemically study the role of STAT3 in pulmonary epithelial cell homeostasis. Using knowledge based gene expression profiling approaches and a conditional system that selectively deleted <italic>Stat3 </italic>in the respiratory epithelium; we identified a large STAT3-dependent network that influences a wide variety of biological processes in type II alveolar cells in the lung.</p></sec><sec><title>Results and Discussion</title><sec><title>Identification of differentially expressed genes in alveolar type II epithelial cells from Stat3<sup>&#x00394;/&#x00394; </sup>mice</title><p>In previous studies Stat3 mRNA and protein expression were markedly reduced in Type II cells isolated from <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice, being less than 10% of control levels [<xref ref-type="bibr" rid="B12">12</xref>]. To identify the RNAs influenced by the conditional deletion of <italic>Stat3</italic><sup>&#x00394;/&#x00394;</sup>, RNAs isolated from alveolar epithelial type II cells of control and <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice were compared using Affymetrix murine genome MOE430 gene chips. The complete dataset can be found at Gene Expression Omnibus (GEO) [<xref ref-type="bibr" rid="B17">17</xref>]; Accession no. GSE6846. Total of 1105 genes were identified as significantly altered using the criteria described in Method. Among them, 791 mRNAs were increased and 314 mRNAs were decreased in response to the deletion of <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>in the lung (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Changes in mRNA expression of a subset of genes including <italic>Malt1, Rnt4, Reg3g, Bcl2l1, Cds2, Cdipt, Fasn, Acox2, Akt2, Gpam, Foxj1, Abca3, Srebf1, Srebf2 and Scap </italic>were validated by real-time RT-PCR. Genes cross validated by RT-PCR are listed in Table <xref ref-type="table" rid="T1">1</xref> and indicated by asterisks (*) in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Comparison of mRNAs by RT-PCR and RNA microarray</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">GENE</td><td align="center">RT-PCR</td><td align="center">Microarray</td><td align="center">P-Value for RT-PCR</td><td align="center">Gene Name</td></tr></thead><tbody><tr><td align="left">Malt1</td><td align="right">3.5</td><td align="right">6.27</td><td align="right">&#x0003c; 0.050</td><td align="left">Mucosa associated lymphoid tissue lymphoma translocation gene 1</td></tr><tr><td align="left">Rtn4</td><td align="right">2.7</td><td align="right">4.86</td><td align="right">&#x0003c; 0.050</td><td align="left">reticulon 4</td></tr><tr><td align="left">Reg3g</td><td align="right">-5.5</td><td align="right">-6.02</td><td align="right">&#x0003c; 0.050</td><td align="left">regenerating islet-derived 3 gamma</td></tr><tr><td align="left">Bcl2l1</td><td align="right">-1.2</td><td align="right">-1.54</td><td align="right">0.053</td><td align="left">Bcl2-like 1</td></tr><tr><td align="left">Akt2</td><td align="right">-1.5</td><td align="right">-1.58</td><td align="right">&#x0003c; 0.050</td><td align="left">thymoma viral proto-oncogene 2</td></tr><tr><td align="left">Abca3</td><td align="right">-2.4</td><td align="right">-1.59</td><td align="right">&#x0003c; 0.050</td><td align="left">ATP-binding cassette, sub-family A (ABC1), member 3</td></tr><tr><td align="left">Scap</td><td align="right">-1.4</td><td align="right">-1.58</td><td align="right">&#x0003c; 0.050</td><td align="left">SREBP cleavage activating protein</td></tr><tr><td align="left">Srebf1</td><td align="right">-1.4</td><td align="right">-1.69</td><td align="right">&#x0003c; 0.050</td><td align="left">sterol regulatory element binding factor 1</td></tr><tr><td align="left">Srebf2</td><td align="right">-1.3</td><td align="right">-1.50</td><td align="right">0.080</td><td align="left">sterol regulatory element binding factor 2</td></tr><tr><td align="left">Cdipt</td><td align="right">-1.8</td><td align="right">-1.54</td><td align="right">&#x0003c; 0.001</td><td align="left">CDP-diacylglycerol--inositol 3-phosphatidyltransferase</td></tr><tr><td align="left">Fasn</td><td align="right">-1.7</td><td align="right">-1.57</td><td align="right">&#x0003c; 0.001</td><td align="left">fatty acid synthase</td></tr><tr><td align="left">Acox2</td><td align="right">-1.5</td><td align="right">-1.67</td><td align="right">&#x0003c; 0.001</td><td align="left">acyl-Coenzyme A oxidase 2</td></tr><tr><td align="left">Cds2</td><td align="right">-2.1</td><td align="right">-1.78</td><td align="right">&#x0003c; 0.001</td><td align="left">CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase)</td></tr><tr><td align="left">Gpam</td><td align="right">-1.5</td><td align="right">-1.54</td><td align="right">&#x0003c; 0.001</td><td align="left">glycerol-3-phosphate acyltransferase</td></tr></tbody></table><table-wrap-foot><p>Note: Fold change of mRNA in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice to control is shown.</p></table-wrap-foot></table-wrap></sec><sec><title>Functional classification of differentially expressed genes revealed the dysregulation of various biological processes in type II epithelial cells from Stat3<sup>&#x00394;/&#x00394; </sup>mice</title><p>Differentially expressed genes were classified according to Gene Ontology (GO) classification on Biological Process. The Fisher Exact Test was used to calculate the probability of each category that was overrepresented in the selected list using the entire MOE430 mouse genome as reference dataset. Deletion of <italic>Stat3 </italic>from type II cells significantly induced the genes involved in protein metabolism, protein transport, chemotaxis and apoptosis and decreased the expression of genes in lipid synthesis and metabolism (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Functional Classification of Genes Differentially Expressed in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" colspan="4">GO Classification of Genes Up-regulated in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice</td></tr></thead><tbody><tr><td align="center"><italic>Term</italic></td><td align="center"><italic>Count</italic></td><td align="center"><italic>%</italic></td><td align="center"><italic>PValue</italic></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Biopolymer modification</td><td align="center">115</td><td align="center">13.94</td><td align="center">7.30E-13</td></tr><tr><td align="left">Cellular protein metabolism</td><td align="center">164</td><td align="center">19.88</td><td align="center">5.83E-10</td></tr><tr><td align="left">Protein transport</td><td align="center">52</td><td align="center">6.30</td><td align="center">2.49E-07</td></tr><tr><td align="left">Phosphate metabolism</td><td align="center">62</td><td align="center">7.52</td><td align="center">3.31E-07</td></tr><tr><td align="left">Chemotaxis</td><td align="center">17</td><td align="center">2.06</td><td align="center">1.38E-06</td></tr><tr><td align="left">Protein kinase cascade</td><td align="center">24</td><td align="center">2.91</td><td align="center">6.83E-06</td></tr><tr><td align="left">Apoptosis</td><td align="center">40</td><td align="center">4.85</td><td align="center">1.69E-05</td></tr><tr><td align="left">Regulation of apoptosis</td><td align="center">29</td><td align="center">3.52</td><td align="center">4.93E-05</td></tr><tr><td align="left">Positive regulation of cellular metabolism</td><td align="center">25</td><td align="center">3.03</td><td align="center">9.95E-05</td></tr><tr><td align="left">Cell migration</td><td align="center">19</td><td align="center">2.30</td><td align="center">2.26E-03</td></tr><tr><td align="left">Transcription</td><td align="center">106</td><td align="center">12.85</td><td align="center">2.64E-03</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left" colspan="4">GO Classification of Genes Down-regulated in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center"><italic>Term</italic></td><td align="center"><italic>Count</italic></td><td align="center"><italic>%</italic></td><td align="center"><italic>PValue</italic></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Cellular lipid metabolism</td><td align="center">33</td><td align="center">9.97</td><td align="center">3.60E-13</td></tr><tr><td align="left">Lipid biosynthesis</td><td align="center">21</td><td align="center">6.34</td><td align="center">3.59E-11</td></tr><tr><td align="left">Sterol metabolism</td><td align="center">10</td><td align="center">3.02</td><td align="center">2.96E-07</td></tr><tr><td align="left">Fatty acid metabolism</td><td align="center">14</td><td align="center">4.23</td><td align="center">5.35E-07</td></tr><tr><td align="left">Steroid metabolism</td><td align="center">12</td><td align="center">3.63</td><td align="center">6.83E-06</td></tr><tr><td align="left">Carboxylic acid metabolism</td><td align="center">18</td><td align="center">5.44</td><td align="center">5.84E-04</td></tr><tr><td align="left">Coenzyme metabolism</td><td align="center">10</td><td align="center">3.02</td><td align="center">2.51E-03</td></tr><tr><td align="left">Cellular carbohydrate metabolism</td><td align="center">12</td><td align="center">3.63</td><td align="center">3.98E-03</td></tr><tr><td align="left">Electron transport</td><td align="center">14</td><td align="center">4.23</td><td align="center">2.64E-02</td></tr><tr><td align="left">Phosphate metabolism</td><td align="center">21</td><td align="center">6.34</td><td align="center">3.27E-02</td></tr></tbody></table><table-wrap-foot><p>Note: Gene Ontology Analysis was preformed using public available web-based tool DAVID [81]. Overrepresented biological processes were selected at the threshold of Fisher Exact Test P-Value &#x02264; 0.05 and minimum gene counts belonging to an annotation term &#x02265; 2%.</p></table-wrap-foot></table-wrap></sec><sec><title>Promoter analysis identified putative common regulators of the differentially expressed genes</title><p>To identify putative common transcription factors regulating the type II cell responses to <italic>Stat3 </italic>deletion, promoter region (-2kb to exon1) of differentially expressed genes were searched for overrepresented cis-elements using MatInspector (Genomatix) vertebrate matrix library. In compare with the sequence of random chosen gene promoters, the cis-elements significantly enriched in the promoter region of differentially expressed genes were selected based on a binomial probability calculation and their percentage frequency in our selected gene list (Adjusted p Value &#x0003c; 0.001 and frequency &#x0003e; 50 %). STAT, EGRF, AHRR, SP1F, ZF5F, E2FF, HIFF, SREB and AP2F were the most overrepresented cis-elements and may therefore mediate changes in gene expression in cells from <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice (Table <xref ref-type="table" rid="T3">3</xref>). The finding that STAT was the most enriched cis-elements indicated the identification of a sub-group of potential direct transcriptional targets of <italic>Stat3 </italic>in lung epithelial cells. Sterol regulatory element binding factors (<italic>Srebf1 and 2</italic>, known as important transcriptional regulators of fatty acid and steroid biosynthesis), were significantly decreased in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice. The SREB binding site was overrepresented in differentially expressed genes indicating that it is a potential regulator of the lipid metabolism pathways altered in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice. Other significantly enriched TFBS include SP1F and HIFF. STAT3 and SP1 function cooperatively to activate the C/EBP promoter, the SP1 site being required for IL-6 induction and transactivation by STAT3 [<xref ref-type="bibr" rid="B18">18</xref>]. HIF1A, SP1, SMAD3 AND SMAD4 can form multifactor complex, regulating VEGF and erythropoietin gene transcription through functional cooperation and association [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. Consistent with the promoter analyses and literature findings, the mRNA expression of <italic>Klf5 </italic>(a member of the SP1 family) and <italic>Hif1a</italic>, <italic>Smad3 </italic>and <italic>Smad4 </italic>was simultaneously increased by <italic>Stat3 </italic>deletion, indicating the potential transcriptional complex formation among the corresponding transcription factors.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Enriched TFBS In Genes Differentially Expressed in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><italic>TFBS</italic></td><td align="center"><italic>Count (Diff_Gene)</italic></td><td align="center"><italic>Frequency (Diff_Gene)</italic></td><td align="center"><italic>Count (background)</italic></td><td align="center"><italic>Frequency (background)</italic></td><td align="center"><italic>P</italic>-<italic>Value</italic></td><td align="center">Q-<italic>Value</italic></td></tr></thead><tbody><tr><td align="left">V$STAT</td><td align="center">863</td><td align="center">0.97</td><td align="center">786</td><td align="center">0.79</td><td align="center">4.93E-59</td><td align="center">2.29E-56</td></tr><tr><td align="left">V$EGRF</td><td align="center">850</td><td align="center">0.96</td><td align="center">757</td><td align="center">0.76</td><td align="center">2.92E-57</td><td align="center">1.35E-54</td></tr><tr><td align="left">V$AHRR</td><td align="center">706</td><td align="center">0.80</td><td align="center">544</td><td align="center">0.54</td><td align="center">4.04E-53</td><td align="center">1.87E-50</td></tr><tr><td align="left">V$SP1F</td><td align="center">857</td><td align="center">0.97</td><td align="center">789</td><td align="center">0.79</td><td align="center">2.15E-49</td><td align="center">9.96E-47</td></tr><tr><td align="left">V$ZF5F</td><td align="center">502</td><td align="center">0.57</td><td align="center">321</td><td align="center">0.32</td><td align="center">2.18E-48</td><td align="center">1.01E-45</td></tr><tr><td align="left">V$E2FF</td><td align="center">850</td><td align="center">0.96</td><td align="center">778</td><td align="center">0.78</td><td align="center">1.30E-47</td><td align="center">6.03E-45</td></tr><tr><td align="left">V$HIFF</td><td align="center">564</td><td align="center">0.64</td><td align="center">439</td><td align="center">0.44</td><td align="center">4.66E-30</td><td align="center">2.16E-27</td></tr><tr><td align="left">V$SREB</td><td align="center">513</td><td align="center">0.58</td><td align="center">425</td><td align="center">0.42</td><td align="center">2.76E-17</td><td align="center">1.28E-14</td></tr><tr><td align="left">V$AP2F</td><td align="center">492</td><td align="center">0.56</td><td align="center">420</td><td align="center">0.42</td><td align="center">4.93E-15</td><td align="center">2.29E-12</td></tr></tbody></table><table-wrap-foot><p>Note: promoter sequence (-2000 &#x02013; 0 bps) from 886 out of 1105 differentially genes were available for analysis. The P-Value is calculated using binomial distribution probability. 5 random sets of 1000 mouse gene -2kb promoter regions were used to calculate the background frequency. The Q-Value is calculated using single-step Bonferroni adjustment to control for the multiple comparison effect.</p></table-wrap-foot></table-wrap></sec><sec><title>Pathway analysis revealed known and novel functions of STAT3 in the lung</title><p>Pathway enrichment test is an unbiased way to answer the question, ''Are the differentially expressed genes enriched in certain pathways?'' To address this issue, we compared the overlap of differentially expressed genes in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice with the known biological pathways in KEGG (Kyoto Encyclopedia of Genes and Genomes) using 1) the mouse genome and 2) a list of genes shown to be least changed in response to the <italic>Stat3 </italic>deletion in the gene array as background. Results from both analyses were consistent. Jak-Stat Signaling Pathway, Apoptosis, Cytokine-Cytokine Receptor Interaction, Insulin Signaling Pathway, Mapk Signaling Pathway, Focal Adhesion, and Wnt Signaling Pathway were among the most enriched pathways identified from the analysis of differentially expressed genes (Table <xref ref-type="table" rid="T4">4</xref>). mRNAs mediating steroid biosynthesis and fatty acid metabolism were mostly decreased in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice. The most overrepresented pathways and the differentially expressed genes associated with those pathways are illustrated in Additional files <xref ref-type="supplementary-material" rid="S2">2</xref>. The finding that known <italic>Stat3 </italic>functions, including the Jak-Stat Signaling Pathway were identified from microarray analysis of <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice type II cells using knowledge integration approaches provides support for the utility of the analysis to detect novel pathways regulated by <italic>Stat3</italic>.</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Enriched Pathways In Genes Differentially Expressed in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><italic>Term</italic></td><td align="center"><italic>Count</italic></td><td align="center"><italic>%</italic></td><td align="center"><italic>P-Value</italic></td></tr></thead><tbody><tr><td align="left">Jak-Stat Signaling Pathway</td><td align="center">38</td><td align="center">3.26</td><td align="center">7.56E-09</td></tr><tr><td align="left">Apoptosis</td><td align="center">24</td><td align="center">2.06</td><td align="center">5.04E-06</td></tr><tr><td align="left">Cytokine-Cytokine Receptor Interaction</td><td align="center">43</td><td align="center">3.69</td><td align="center">2.59E-05</td></tr><tr><td align="left">Insulin Signaling Pathway</td><td align="center">28</td><td align="center">2.40</td><td align="center">5.53E-05</td></tr><tr><td align="left">Mapk Signaling Pathway</td><td align="center">45</td><td align="center">3.86</td><td align="center">8.51E-05</td></tr><tr><td align="left">Focal Adhesion</td><td align="center">37</td><td align="center">3.17</td><td align="center">1.55E-04</td></tr><tr><td align="left">Wnt Signaling Pathway</td><td align="center">28</td><td align="center">2.40</td><td align="center">1.68E-04</td></tr></tbody></table><table-wrap-foot><p>Overrepresented pathways were identified by comparison the overlap of differentially expressed genes and all genes in MOE430 mouse genome (reference) with the known KEGG pathways. A pathway is considered to be over-represented when a probability P-Value &#x02264; 0.01 and gene frequency (genes in the pathway/total number of differentially expressed genes) &#x02265; 2%.</p></table-wrap-foot></table-wrap></sec><sec><title>Stat3 influences protein metabolism in lung type II cells</title><p>''Protein metabolism'' was the most enriched biological process (5.83E-10), accounting for 20% of the induced genes caused by the deletion of <italic>Stat3</italic>. More than 40 genes encoding proteins involved in protein ubiquitination/ubiquitin cycle were present (Table <xref ref-type="table" rid="T5">5</xref>). Of interest, Casitas B-lineage lymphoma b (<italic>Cblb</italic>) was increased 7.3 fold. CBLB is a member of Cbl ubiquitin ligases (E3) protein family that are tyrosine-phosphorylated in response to a wide variety of receptor mediated stimuli, including epidermal growth factor receptors, cytokine receptors such as colony stimulating factor family receptors (increased 2&#x02013;3 fold in the <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>cells) and immune complex receptors such as <italic>Fcgr2b </italic>(increased 2.7 fold). CBLB functions as an adaptor protein that regulates many signal-transduction pathways including JAK-STAT signaling pathways through its ability to interact with critical signaling molecules [<xref ref-type="bibr" rid="B22">22</xref>]. The expression of genes encoding known CBLB binding partners was significantly increased in type II cells from the <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice, including SYK kinase (increased 4 fold), JAK2 (increased 2.1 fold), PKC (increased 2.6 fold), phosphatidylinositol 3-kinase (<italic>Pik3r1 </italic>increased 1.8 fold, <italic>Pik3c2a </italic>increased 3 fold), adenylate cyclase-associated protein 1 (<italic>Cap1 </italic>increased 5 fold) and <italic>Crk </italic>(increased 2.5 fold). These signaling molecules can in turn modulate various down stream signaling cascades including those mediated by small G-proteins (multiple members of RAS oncogene family were induced 2&#x02013;3 fold), as well as PI3K/AKT mediated signaling and <italic>Nfat </italic>induction (increased 4.1 fold) [<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B27">27</xref>]. CBLB physically interacts with another ubiquitin-protein ligase, NEDD4 (increased 3.8 fold), an interaction that reverses CBLB effects by targeting CBLB for ubiquitination and proteasomal degradation [<xref ref-type="bibr" rid="B28">28</xref>]. SLIM is a known E3 ubiquitin ligase specifically interacts with activated STAT1 and STAT4, inducing their ubiquitination and degradation [<xref ref-type="bibr" rid="B29">29</xref>]. We speculate that CBLB may act in a similar manner to regulate STAT3 signaling. In addition, SUMO1 and SUMO1 specific peptidase 2 were both increased more than 2 fold in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice. SUMO1 can covalently modify many targets including STAT1 and glucocorticoid receptor NR3C1 (increased 5 fold) and regulate protein stability and transcriptional activity [<xref ref-type="bibr" rid="B30">30</xref>]. Taken together, deletion of STAT3 activates a number of molecules regulating protein metabolism, stability and routing, indicating the potential role of ubiquitination and sumoylation in cytokine signaling and STAT3 activation that influences cellular adaptation.</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Genes In Ubiquitin Cycle Were Largely Induced In <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>Mice</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><italic>UniGene ID</italic></td><td align="center"><italic>Fold</italic></td><td align="center"><italic>P-Value</italic></td><td align="left"><italic>Gene Symbol</italic></td><td align="left"><italic>Gene Title</italic></td></tr></thead><tbody><tr><td align="left">Mm.328206</td><td align="center">7.29</td><td align="center">9.98E-04</td><td align="left">Cblb</td><td align="left">Casitas B-lineage lymphoma b</td></tr><tr><td align="left">Mm.260635</td><td align="center">4.56</td><td align="center">6.34E-03</td><td align="left">Axot</td><td align="left">Axotrophin</td></tr><tr><td align="left">Mm.98668</td><td align="center">3.79</td><td align="center">6.93E-05</td><td align="left">Nedd4l</td><td align="left">neural precursor cell expressed, developmentally down-regulated gene 4-like</td></tr><tr><td align="left">Mm.276229</td><td align="center">3.37</td><td align="center">1.41E-03</td><td align="left">Fbxo30</td><td align="left">F-box protein 30</td></tr><tr><td align="left">Mm.258476</td><td align="center">3.30</td><td align="center">6.58E-03</td><td align="left">Tbl1x</td><td align="left">transducin (beta)-like 1 X-linked</td></tr><tr><td align="left">Mm.28017</td><td align="center">3.22</td><td align="center">3.62E-03</td><td align="left">Fbxw11</td><td align="left">F-box and WD-40 domain protein 11</td></tr><tr><td align="left">Mm.16974</td><td align="center">3.03</td><td align="center">1.66E-04</td><td align="left">Usp47</td><td align="left">ubiquitin specific peptidase 47</td></tr><tr><td align="left">Mm.388965</td><td align="center">3.01</td><td align="center">8.38E-04</td><td align="left">Rnf12</td><td align="left">Ring finger protein 12</td></tr><tr><td align="left">Mm.41711</td><td align="center">2.87</td><td align="center">1.43E-03</td><td align="left">Pja2</td><td align="left">Praja 2, RING-H2 motif containing (Pja2), transcript variant 2, mRNA</td></tr><tr><td align="left">Mm.214746</td><td align="center">2.75</td><td align="center">1.78E-03</td><td align="left">Fbxl3</td><td align="left">F-box and leucine-rich repeat protein 3</td></tr><tr><td align="left">Mm.242646</td><td align="center">2.75</td><td align="center">1.83E-03</td><td align="left">Usp9x</td><td align="left">ubiquitin specific protease 9, X chromosome</td></tr><tr><td align="left">Mm.9002</td><td align="center">2.70</td><td align="center">6.26E-04</td><td align="left">Ube3a</td><td align="left">ubiquitin protein ligase E3A</td></tr><tr><td align="left">Mm.30051</td><td align="center">2.53</td><td align="center">4.86E-04</td><td align="left">Rnf10</td><td align="left">Ring finger protein 10</td></tr><tr><td align="left">Mm.362118</td><td align="center">2.41</td><td align="center">9.26E-04</td><td align="left">Sumo1</td><td align="left">SMT3 suppressor of mif two 3 homolog 1 (yeast) (Sumo1)</td></tr><tr><td align="left">Mm.328135</td><td align="center">2.36</td><td align="center">3.35E-04</td><td align="left">Rfwd2</td><td align="left">Constitutive photomorphogenic protein (Cop1)</td></tr><tr><td align="left">Mm.290908</td><td align="center">2.34</td><td align="center">3.27E-04</td><td align="left">Birc6</td><td align="left">baculoviral IAP repeat-containing 6</td></tr><tr><td align="left">Mm.180052</td><td align="center">2.34</td><td align="center">4.84E-03</td><td align="left">Ube2d2</td><td align="left">Ubiquitin-conjugating enzyme E2D 2</td></tr><tr><td align="left">Mm.391601</td><td align="center">2.29</td><td align="center">9.75E-03</td><td align="left">Ube2d3</td><td align="left">ubiquitin-conjugating enzyme E2D 3</td></tr><tr><td align="left">Mm.4480</td><td align="center">2.25</td><td align="center">1.28E-03</td><td align="left">Rbbp6</td><td align="left">Retinoblastoma binding protein 6 (Rbbp6)</td></tr><tr><td align="left">Mm.319512</td><td align="center">2.24</td><td align="center">5.65E-03</td><td align="left">Hip2</td><td align="left">huntingtin interacting protein 2</td></tr><tr><td align="left">Mm.12665</td><td align="center">2.19</td><td align="center">1.60E-02</td><td align="left">Cul3</td><td align="left">cullin 3</td></tr><tr><td align="left">Mm.244179</td><td align="center">2.12</td><td align="center">3.75E-03</td><td align="left">Herc1</td><td align="left">Hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1</td></tr><tr><td align="left">Mm.392272</td><td align="center">2.10</td><td align="center">4.55E-04</td><td align="left">Smurf2</td><td align="left">SMAD specific E3 ubiquitin protein ligase 2</td></tr><tr><td align="left">Mm.297431</td><td align="center">1.95</td><td align="center">2.84E-03</td><td align="left">Senp2</td><td align="left">SUMO/sentrin specific peptidase 2</td></tr><tr><td align="left">Mm.253542</td><td align="center">1.94</td><td align="center">1.53E-02</td><td align="left">Rnf138</td><td align="left">ring finger protein 138</td></tr><tr><td align="left">Mm.235407</td><td align="center">1.94</td><td align="center">1.32E-02</td><td align="left">Ube2v2</td><td align="left">ubiquitin-conjugating enzyme E2 variant 2</td></tr><tr><td align="left">Mm.392862</td><td align="center">1.93</td><td align="center">3.54E-03</td><td align="left">Arih1</td><td align="left">ariadne ubiquitin-conjugating enzyme E2 binding protein homolog</td></tr><tr><td align="left">Mm.78312</td><td align="center">1.89</td><td align="center">1.07E-02</td><td align="left">Wwp1</td><td align="left">WW domain containing E3 ubiquitin protein ligase 1</td></tr><tr><td align="left">Mm.44876</td><td align="center">1.84</td><td align="center">3.88E-03</td><td align="left">Trim2</td><td align="left">tripartite motif protein 2</td></tr></tbody></table></table-wrap></sec><sec><title>STAT3 influences phosphate metabolism and protein kinase cascade in lung type II cells</title><p>Expression of genes regulating ''Phosphate metabolism'' and ''protein kinase cascade'' were significantly increased in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice (3.1E-07 and 1.38E-06, respectively), accounting for 7.5% of total induced genes (Table <xref ref-type="table" rid="T6">6</xref>). Expression of genes encoding a number of kinase that phosphorylate STAT3 in vivo or in vitro were increased [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B35">35</xref>], including Janus kinase 1 and 2 (increased 3.1 and 2.6 fold, respectively), ribosomal protein S6 kinase polypeptide 3 (<italic>Rps6ka3</italic>, increased 3.1 fold), met proto-oncogene (<italic>Met</italic>, increased 4.2 fold), mitogen activated protein kinase 8 (<italic>Mapk8</italic>, increased 4.7 fold) and Dual-specificity tyrosine-phosphorylation regulated kinase 1a (<italic>Dyrk1a</italic>, increased 2.6 fold). The increased expression of these genes indicates a potential compensatory mechanism related to the lack of activation of STAT3 or its targets.</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Genes In Phosphate Metabolism Were Largely Induced In <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>Mice</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><italic>UniGene ID</italic></td><td align="center"><italic>Fold</italic></td><td align="center"><italic>P-Value</italic></td><td align="left"><italic>Gene Symbol</italic></td><td align="left"><italic>Gene Title</italic></td></tr></thead><tbody><tr><td align="left">Mm.188734</td><td align="center">8.32</td><td align="center">3.47E-05</td><td align="left">Adk</td><td align="left">Adenosine kinase</td></tr><tr><td align="left">Mm.21495</td><td align="center">4.70</td><td align="center">1.82E-03</td><td align="left">Mapk8</td><td align="left">Mitogen activated protein kinase 8</td></tr><tr><td align="left">Mm.3879</td><td align="center">4.69</td><td align="center">4.29E-05</td><td align="left">Hif1a</td><td align="left">Hypoxia inducible factor 1, alpha subunit</td></tr><tr><td align="left">Mm.86844</td><td align="center">4.18</td><td align="center">1.89E-03</td><td align="left">Met</td><td align="left">Met proto-oncogene</td></tr><tr><td align="left">Mm.225505</td><td align="center">4.09</td><td align="center">2.32E-03</td><td align="left">Chka</td><td align="left">Choline kinase alpha</td></tr><tr><td align="left">Mm.375031</td><td align="center">4.02</td><td align="center">1.39E-03</td><td align="left">Syk</td><td align="left">Spleen tyrosine kinase</td></tr><tr><td align="left">Mm.327591</td><td align="center">3.60</td><td align="center">1.26E-03</td><td align="left">Cask</td><td align="left">Calcium/calmodulin-dependent serine protein kinase</td></tr><tr><td align="left">Mm.248647</td><td align="center">3.42</td><td align="center">2.36E-02</td><td align="left">Pi4k2b</td><td align="left">Phosphatidylinositol 4-kinase type 2 beta</td></tr><tr><td align="left">Mm.255822</td><td align="center">3.31</td><td align="center">2.08E-04</td><td align="left">Camk2d</td><td align="left">Calcium/calmodulin-dependent protein kinase II, delta</td></tr><tr><td align="left">Mm.25559</td><td align="center">3.30</td><td align="center">7.41E-03</td><td align="left">Stk17b</td><td align="left">Serine/threonine kinase 17b (apoptosis-inducing)</td></tr><tr><td align="left">Mm.328476</td><td align="center">3.15</td><td align="center">1.45E-02</td><td align="left">Rps6ka3</td><td align="left">Ribosomal protein S6 kinase polypeptide 3</td></tr><tr><td align="left">Mm.289657</td><td align="center">3.14</td><td align="center">1.66E-04</td><td align="left">Jak1</td><td align="left">Janus kinase 1</td></tr><tr><td align="left">Mm.3810</td><td align="center">3.08</td><td align="center">7.64E-03</td><td align="left">Pik3c2a</td><td align="left">Phosphatidylinositol 3-kinase, C2 domain</td></tr><tr><td align="left">Mm.202606</td><td align="center">3.04</td><td align="center">1.02E-04</td><td align="left">Mast4</td><td align="left">Microtubule associated serine/threonine kinase family member 4</td></tr><tr><td align="left">Mm.309867</td><td align="center">2.88</td><td align="center">3.93E-04</td><td align="left">Ptk9</td><td align="left">Protein tyrosine kinase 9</td></tr><tr><td align="left">Mm.280125</td><td align="center">2.86</td><td align="center">3.15E-03</td><td align="left">Crk</td><td align="left">v-crk sarcoma virus CT10 oncogene homolog (avian)</td></tr><tr><td align="left">Mm.272548</td><td align="center">2.82</td><td align="center">4.37E-04</td><td align="left">Etnk1</td><td align="left">Ethanolamine kinase 1</td></tr><tr><td align="left">Mm.197552</td><td align="center">2.74</td><td align="center">1.10E-03</td><td align="left">Tgfbr1</td><td align="left">Transforming growth factor, beta receptor I</td></tr><tr><td align="left">Mm.262330</td><td align="center">2.66</td><td align="center">1.54E-02</td><td align="left">Stk3</td><td align="left">Serine/threonine kinase 3 (Ste20, yeast homolog)</td></tr><tr><td align="left">Mm.295263</td><td align="center">2.65</td><td align="center">1.43E-03</td><td align="left">Dcamkl1</td><td align="left">Double cortin and calcium/calmodulin-dependent protein kinase-like 1</td></tr><tr><td align="left">Mm.222178</td><td align="center">2.57</td><td align="center">2.58E-04</td><td align="left">Prkca</td><td align="left">Protein kinase C, alpha (Prkca), mRNA</td></tr><tr><td align="left">Mm.310973</td><td align="center">2.56</td><td align="center">5.12E-04</td><td align="left">Dyrk1a</td><td align="left">Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a</td></tr><tr><td align="left">Mm.313594</td><td align="center">2.50</td><td align="center">5.58E-03</td><td align="left">Mpp5</td><td align="left">Palmitoylated 5 (MAGUK p55 subfamily member 5)</td></tr><tr><td align="left">Mm.6710</td><td align="center">2.49</td><td align="center">3.65E-02</td><td align="left">Rock1</td><td align="left">Rho-associated coiled-coil forming kinase 1</td></tr><tr><td align="left">Mm.440470</td><td align="center">2.46</td><td align="center">3.16E-03</td><td align="left">Crk7</td><td align="left">CDC2-related kinase 7</td></tr><tr><td align="left">Mm.389061</td><td align="center">2.36</td><td align="center">1.34E-03</td><td align="left">Pftk1</td><td align="left">PFTAIRE protein kinase 1 (Pftk1), mRNA</td></tr><tr><td align="left">Mm.244236</td><td align="center">2.34</td><td align="center">8.50E-03</td><td align="left">Pkn2</td><td align="left">Protein kinase N2</td></tr><tr><td align="left">Mm.288141</td><td align="center">2.25</td><td align="center">7.64E-03</td><td align="left">Rp2h</td><td align="left">Retinitis pigmentosa 2 homolog (human)</td></tr><tr><td align="left">Mm.31672</td><td align="center">2.21</td><td align="center">4.65E-04</td><td align="left">Cdk6</td><td align="left">Cyclin-dependent kinase 6 (Cdk6), mRNA</td></tr><tr><td align="left">Mm.215171</td><td align="center">2.20</td><td align="center">5.62E-04</td><td align="left">Trpm6</td><td align="left">Transient receptor potential cation channel, subfamily M, member 6</td></tr><tr><td align="left">Mm.3994</td><td align="center">2.18</td><td align="center">3.98E-04</td><td align="left">Dusp16</td><td align="left">Dual specificity phosphatase 16</td></tr><tr><td align="left">Mm.136511</td><td align="center">2.17</td><td align="center">5.10E-04</td><td align="left">Tlk1</td><td align="left">MKIAA0137 protein</td></tr><tr><td align="left">Mm.332231</td><td align="center">2.16</td><td align="center">3.01E-03</td><td align="left">Magi2</td><td align="left">Membrane associated guanylate kinase, WW and PDZ domain containing 2</td></tr><tr><td align="left">Mm.16340</td><td align="center">2.13</td><td align="center">1.50E-02</td><td align="left">Fgfr2</td><td align="left">Fibroblast growth factor receptor 2</td></tr><tr><td align="left">Mm.275839</td><td align="center">2.13</td><td align="center">1.00E-02</td><td align="left">Jak2</td><td align="left">Janus kinase 2</td></tr><tr><td align="left">Mm.393114</td><td align="center">2.08</td><td align="center">7.62E-04</td><td align="left">Csnk1a1</td><td align="left">Casein kinase 1, alpha 1</td></tr><tr><td align="left">Mm.17918</td><td align="center">2.08</td><td align="center">7.94E-04</td><td align="left">Marcksl1</td><td align="left">MARCKS-like 1</td></tr><tr><td align="left">Mm.368668</td><td align="center">2.06</td><td align="center">6.49E-04</td><td align="left">Csnk1g3</td><td align="left">Casein kinase 1, gamma 3 (Csnk1g3), mRNA</td></tr><tr><td align="left">Mm.291936</td><td align="center">2.01</td><td align="center">8.02E-03</td><td align="left">Map4k5</td><td align="left">Mitogen-activated protein kinase kinase kinase kinase 5</td></tr><tr><td align="left">Mm.35290</td><td align="center">-2.00</td><td align="center">1.42E-02</td><td align="left">Ripk4</td><td align="left">Receptor-interacting serine-threonine kinase 4</td></tr><tr><td align="left">Mm.36006</td><td align="center">-2.39</td><td align="center">1.22E-03</td><td align="left">Ak7</td><td align="left">Adenylate kinase 7</td></tr><tr><td align="left">Mm.306163</td><td align="center">-2.68</td><td align="center">8.63E-03</td><td align="left">Prkar1b</td><td align="left">Protein kinase, cAMP dependent regulatory, type I beta</td></tr><tr><td align="left">Mm.7373</td><td align="center">-2.71</td><td align="center">1.05E-03</td><td align="left">Per1</td><td align="left">Period homolog 1 (Drosophila)</td></tr><tr><td align="left">Mm.32831</td><td align="center">-2.96</td><td align="center">2.47E-02</td><td align="left">Wif1</td><td align="left">Wnt inhibitory factor 1</td></tr><tr><td align="left">Mm.44442</td><td align="center">-3.76</td><td align="center">2.45E-04</td><td align="left">Kndc1</td><td align="left">Kinase non-catalytic C-lobe domain (KIND) containing 1</td></tr></tbody></table></table-wrap></sec><sec><title>STAT3 influences lipid homeostasis in lung type II cells</title><p>Expression of genes encoding sterol regulatory element binding factor 1 and 2 (<italic>Srebf1 </italic>and <italic>Srebf2</italic>), their cleavage activating protein (<italic>Scap</italic>) and multiple SREBP target genes involved in lipid metabolism were decreased in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice type II cells. As depicted in Figure <xref ref-type="fig" rid="F1">1</xref>, genes dedicated to the biosynthesis of fatty acid, phospholipid and cholesterol were down regulated, with the exception of 3-hydroxy-3-methylglutaryl-Coenzyme A synthase (<italic>Hmgcs</italic>), which was increased. HMGCS participates in other metabolic pathways, including valine, leucine and isoleucine degradation (KEGG 00280). This analysis indicates that metabolic pathways regulating fatty acid, phospholipid, and cholesterol biosynthesis were coordinately decreased after deletion of <italic>Stat3 </italic>in type II cells, supporting an important role of STAT3 in regulating lipids biosynthesis in the lung. LDL receptor (<italic>Ldlr</italic>), mediating cholesterol uptake, and ATP-binding cassette A3 (<italic>Abca3</italic>), important for phospholipid transport, lamellar body formation and pulmonary surfactant secretion in alveolar type II cells were decreased in the <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice cells [<xref ref-type="bibr" rid="B36">36</xref>-<xref ref-type="bibr" rid="B38">38</xref>]. Recent <italic>in vitro </italic>studies from our group confirmed the direct binding of SREBP1c to the Abca3 promoter (Besnard et.al, submitted for publication). On the other hand, the increased expression of <italic>Abca1</italic>, a key facilitator of cellular cholesterol and phospholipid export [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>] and high density lipoprotein binding protein (<italic>Hdlbp</italic>), which may function in the removal of excess cellular cholesterol, suggests that cholesterol and phospholipid clearance were induced after deletion of <italic>Stat3</italic>. Adenosine kinase (<italic>Adk</italic>), was increased 8.2 fold. Cellular role of ADK in lipid metabolism is somewhat controversial [<xref ref-type="bibr" rid="B41">41</xref>], <italic>Adk </italic>deficient mice developed neonatal hepatic steatosis and die within 14 days with fatty liver [<xref ref-type="bibr" rid="B42">42</xref>]. Increased expression of lipid export genes and decreased expression of genes mediating lipid biosynthesis likely cause a reduction of total lipids level in the type II cells of <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Genes involved in lipids biosynthesis and clearance pathways were altered in type II cells from <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice</bold>. A. <italic>Srebf1 </italic>and <italic>Srebf2 </italic>regulate genes encoding the major metabolic enzymes in the fatty acid, cholesterol and phospholipids biosynthesis. The arrow (&#x02191;) indicates that the mRNA level was induced in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice; (&#x02193;) indicates the mRNA level was reduced in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice. Gene symbols, descriptions and the expression changes are listed in panel B.</p></caption><graphic xlink:href="1471-2164-8-455-1"/></fig><p>Previous studies demonstrated the susceptibility of <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice to lung injury and death related to surfactant dysfunction [<xref ref-type="bibr" rid="B12">12</xref>]. Consistent with our prediction from the present mRNA microarray analysis, the saturated phosphatidycholine (SatPC) content in bronchoalveolar lavage fluid was significantly decreased in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice (Figure <xref ref-type="fig" rid="F2">2</xref>). Significantly decreased SatPC synthesis and abnormalities in lamellar body numbers and morphology were also observed in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice (data not shown). Taken together, a number of genes regulating surfactant lipid homeostasis were altered in type II cells isolated from the Stat3<sup>&#x00394;/&#x00394; </sup>mice, consistent with biochemical, functional, and morphologic changes in the surfactant system that is exacerbated by oxidant stress [<xref ref-type="bibr" rid="B12">12</xref>] or expose to pathogens [<xref ref-type="bibr" rid="B13">13</xref>].</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Surfactant saturated phosphatidylcholine (SatPC)</bold> was significantly decreased in bronchoalveolar lavage fluid from the <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice, n = 8 per group. Aliquots of BALF were extracted with chloroform/methanol (2:1) and SatPC was isolated with osmium tetroxide followed by measurement of phosphorus as described previously [12]. Statistical differences were analyzed by Student t-test.</p></caption><graphic xlink:href="1471-2164-8-455-2"/></fig></sec><sec><title>Role of Akt in Stat3 regulated lipid metabolism</title><p>Our observations support the view that the decrease in SREBP, at least in part, results in decreased expression of genes regulating lipid biosynthesis and metabolism in type II cells from <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice. SREBPs are master regulators of lipid metabolism. The transcriptional targets, and the pathways mediated by SREBP in liver have been well studied [<xref ref-type="bibr" rid="B43">43</xref>]. SREBPs are expressed in the developing lung, SREB1c increases in the developing lung concomitantly with the perinatal increase in surfactant and lipid synthesis, surfactant protein and <italic>Abca3 </italic>expression, genes critical for surfactant function.</p><p>However, the role of Stat3 in regulating SREBP and associated lipid metabolism in the lung is largely unknown. In the present analysis, we sought to identify mechanisms by which <italic>Stat3 </italic>regulates SREBPs and associated lipid biosynthesis pathways in alveolar type II cells in the lung. The regulation of SREBPs occurs at both transcriptional and post-transcriptional levels. The post-transcriptional regulation requires SCAP. Cre-mediated disruption of <italic>Scap </italic>significantly reduced <italic>Srebf1 and 2 </italic>levels as well as SREBP target gene expression in liver [<xref ref-type="bibr" rid="B44">44</xref>]. There are multiple potential STAT sites on the <italic>Scap </italic>promoter. Thus, <italic>Stat3 </italic>may influence lipid biosynthesis through the transcriptional regulation of <italic>Scap</italic>. At transcriptional level, nuclear hormone receptors (<italic>Nr1h2 and Nr1h3</italic>) and Pgc1-alpha and beta are known to regulate SREBPs expression in liver. Increased expression of <italic>Srebf1 </italic>and <italic>Fasn </italic>was associated with increased hepatic triglyceride content in <italic>Stat3 </italic>deficient mice [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. In the present study, expression of SREBP and their down stream targets were decreased in type II cells from <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice (a finding that contrast with the findings in the liver) without changes in other known regulators such as <italic>Nr1h2, Nr1h3</italic>, <italic>Pgc1-alpha </italic>or <italic>Pgc1-beta</italic>, indicating the likely presence of alternative regulatory mechanisms in lung cells.</p><p>We hypothesize that AKT plays an important role in <italic>Stat3 </italic>regulated SREBP expression and associated lipogenesis in lung based on the following observations: 1) Protein and mRNA levels of <italic>Akt </italic>were increased in cells constitutively expressing active <italic>Stat3 </italic>and were reduced after <italic>Stat3 </italic>depletion [<xref ref-type="bibr" rid="B46">46</xref>]. STAT3 binds to <italic>Akt1 </italic>promoter was confirmed by ChIP assay [<xref ref-type="bibr" rid="B47">47</xref>], suggesting that A <italic>kt </italic>maybe a direct transcriptional target of <italic>Stat3</italic>. AKT, on the other hand, inhibits <italic>Stat3 </italic>transcriptional activity and phosphorylation [<xref ref-type="bibr" rid="B48">48</xref>]. Decreased <italic>Akt </italic>gene expression seen after deletion of <italic>Stat3 </italic>may represent a direct effect of <italic>Stat3 </italic>deficiency or to a negative regulatory response to STAT3 deficiency, 2) AKT activation induces both <italic>Srebf1 </italic>and <italic>Srebf2 </italic>mRNAs and proteins as well as key enzymes in the cholesterol, fatty acid and membrane lipid biosynthesis pathways [<xref ref-type="bibr" rid="B49">49</xref>], 3) Multiple lines of evidence suggest that PI3K influences <italic>Stat3 </italic>activation. STAT3 binds directly to the PI3K regulatory subunits [<xref ref-type="bibr" rid="B50">50</xref>-<xref ref-type="bibr" rid="B52">52</xref>]. The expression of genes encoding for several PI3K subunits were altered after deletion of <italic>Stat3 </italic>(see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>), supporting the involvement of PI3K/Akt signaling in <italic>Stat3 </italic>regulated bioprocesses in lung, and 4) Since AKT physically interacts with FOXA2 and regulates FOXA2-dependent transcriptional activity [<xref ref-type="bibr" rid="B53">53</xref>], the effects of AKT may be mediated, in part, via <italic>Foxa2. Foxa2 </italic>expression was reduced more than 2 fold in cells from the <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice. FOXA2 regulates lipid metabolism in both lung and liver [<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>]. Deletion of either <italic>Stat3 </italic>or <italic>Foxa2 </italic>resulting in decreased expression of a number of the overlapping genes that play important roles in surfactant homeostasis including Abca3 [<xref ref-type="bibr" rid="B55">55</xref>]. Thus, interactions between AKT and FOXA2 represent another potential mechanism by which lipid metabolism is influenced in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice.</p></sec><sec><title>Stat3 influences expression of genes mediating apoptosis and cell survival</title><p>Many genes modulating apoptosis/cell survival were altered in response to the deletion of <italic>Stat3 </italic>from type II cells, including multiple Bcl-2 family members (<italic>Bcl2, Bcl2l1, Mcl1, Bcl2l11 </italic>and <italic>Bad</italic>), caspase 3 (<italic>Casp3</italic>), FADD-like apoptosis regulator (<italic>Cflar</italic>, also known as Flip), mucosa associated lymphoid tissue lymphoma translocation gene 1 (<italic>Malt1</italic>), prostaglandin-endoperoxide synthase 2 (<italic>Ptgs2</italic>) and nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor, <italic>Nr3c1</italic>). In depth literature mining identified more apoptosis related genes than did analysis by Gene Ontology annotation. As depicted in Figure <xref ref-type="fig" rid="F3">3</xref>, our study indicates that STAT3 regulates apoptosis in a complex manner via processes that occur in multiple intracellular locations. Thus, STAT3 appears to serve as key regulator of apoptosis in alveolar type II cells. Among those apoptosis related genes, <italic>Malt1, Ptgs2 </italic>and <italic>Nr3c1 </italic>were strongly induced (&#x0003e; 5 fold in compare with control). MALT1 interacts with BCL10 (increased 2 fold in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice). The formation of this complex is essential for NF-kappaB activation that, in turn, play a role in cell survival. IKKB phosphorylates BCL10 in its MALT1 interaction domain, causing BCL10 and MALT1 to disassociate, resulting in attenuation of NFKB signaling and cytokine production [<xref ref-type="bibr" rid="B56">56</xref>,<xref ref-type="bibr" rid="B57">57</xref>]. PTGS2 also known as COX-2, a key enzyme in prostaglandin biosynthesis, that is highly expressed in alveolar type II cells. The expression of <italic>Ptgs2 </italic>is increased in epithelial tumors, including non-small cell lung and prostate cancers via activation of the IL-6/GP130/<italic>STAT3 </italic>signaling pathway [<xref ref-type="bibr" rid="B58">58</xref>]. This pathway could contribute to tumor formation by promotion of tumor cell resistance to apoptosis via inhibitor of apoptosis (IAP)-dependent mechanism [<xref ref-type="bibr" rid="B58">58</xref>,<xref ref-type="bibr" rid="B59">59</xref>]. Consistent with these observations, <italic>Ptgs2</italic>, <italic>Il6st </italic>and two of the IAP family members (<italic>Birc4 </italic>and <italic>Birc6</italic>) were correspondingly induced in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>cells (5.7, 1.7, 3.2 and 2.3 fold respectively). <italic>Nr3c1 </italic>(increased 5.1 fold) encodes a receptor for glucocorticoids that can act as both a transcription factor and as a regulator of other transcription factors. STAT3 and NR3C1 physically interact to mediate effect of glucocorticoid on the IL-6-mediated inflammatory response [<xref ref-type="bibr" rid="B60">60</xref>-<xref ref-type="bibr" rid="B62">62</xref>]. NR3C1 also interacts with stress-responsive transcription factors (<italic>Hif1a</italic>, increased 4.7 fold), mitogen activated protein kinase 8 (<italic>Mapk8 or Jnk</italic>, increased 4.7 fold) and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide (<italic>Ywhal</italic>, increased 3.3 fold), a 14-3-3 family of proteins implicated in the pathogenesis of small cell lung cancer [<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B64">64</xref>].</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Genes involved in apoptotic pathways were altered in type II cells isolated from <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice</bold>. Genes associated with apoptosis were identified via literature mining using Pathway Studio 4.0 (Ariadne Genomics, Inc.). STAT3 regulates apoptosis positively and negatively, via processes occurring in multiple intracellular compartments. Genes up-regulated in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice are framed in red. Genes down-regulated in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice are framed in green. Each dashed line demarcated with a larger dot linking "apoptosis" and each gene node indicates a regulatory relationship based on the literature references. Regulatory relationships are denoted by line colors (green, positive regulation; red, negative regulation; and gray, regulation direction is unknown).</p></caption><graphic xlink:href="1471-2164-8-455-3"/></fig><p>STAT3 is likely to regulate apoptosis by multiple mechanisms including gene transcription. Bcl-xL is the direct transcription target of STAT3[<xref ref-type="bibr" rid="B65">65</xref>]. STAT3 can serve as an anti-apoptotic factor by transcriptional up-regulating the expression of Bcl-xL [<xref ref-type="bibr" rid="B66">66</xref>]. The decrease of Bcl-xL may represent a direct response to <italic>Stat3 </italic>deletion. The fact that expression of Bcl-xL blocked the apoptotic effects of the adenovirus in lung injury suggested that Bcl-xL may mediate the role of STAT3 in the regulation and survival of the respiratory epithelium [<xref ref-type="bibr" rid="B13">13</xref>]. The Pi3k-Akt pathway represents a second mechanism by which STAT3 influences cytoprotection. Pi3k-Akt signaling mediates a wide range of down stream targets to regulate apoptosis [<xref ref-type="bibr" rid="B67">67</xref>]. For example, AKT phosphorylates multiple Bcl-2 family members, including BAD and Bcl-xL [<xref ref-type="bibr" rid="B68">68</xref>], inhibits caspase 3 activation [<xref ref-type="bibr" rid="B66">66</xref>] and blocks cytochrome C release from mitochondria [<xref ref-type="bibr" rid="B69">69</xref>]. Another mechanism by which STAT3 modulates apoptosis is through protein-protein interactions. Bcl-xL is a direct transcriptional target of STAT3; Bcl-xL interacts with VDAC1 to regulate the outer mitochondrial membrane channel induce apoptosis [<xref ref-type="bibr" rid="B70">70</xref>,<xref ref-type="bibr" rid="B71">71</xref>]. CASP3 can interact with multiple apoptosis proteins including CFLAR, BIRC4 and 6, BCL2 and APP [<xref ref-type="bibr" rid="B72">72</xref>-<xref ref-type="bibr" rid="B75">75</xref>]. The expression of <italic>Casp3 </italic>as well as its interaction partners was induced in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice. NR3C1 has both pro- and anti-apoptotic effects. NR3C1 physically interact with STAT3, HIF1A, MAPK8, YWHAL [<xref ref-type="bibr" rid="B63">63</xref>,<xref ref-type="bibr" rid="B64">64</xref>,<xref ref-type="bibr" rid="B76">76</xref>]; these stress-responsive transcription factors and signaling molecules were largely induced in the present array from Stat3<sup>&#x00394;/&#x00394; </sup>type II alveolar epithelial cells. The close transcriptional communication and physical interactions among these transcriptional regulators likely play a critical role in regulating the balance of apoptosis and cell survival. In the present study, effects of STAT3 deletion were assessed in type II epithelial cells purified from the adult mouse lung. mRNA was isolated immediately after isolation to avoid cell culture dependent alteration in gene expression. It is possible that the cells have undergone added cellular stress during protease treatment, isolation and purification, which in turn may influence the expression of genes. Our results support the view that STAT3 regulates the balance between a subset of pro- and anti-apoptotic genes, determining the cell death or survival through multiple mechanisms. Consistent with the present microarray prediction, cleaved caspase-3 and TUNEL positive cells were significantly increased in Stat3<sup>&#x00394;/&#x00394; </sup>mice following adenoviral infection and the apoptosis can be blocked by expression of Bcl-xL [<xref ref-type="bibr" rid="B13">13</xref>].</p></sec></sec><sec><title>Conclusion</title><p>Our previous studies demonstrated that Stat3 plays critical role in cyto-protection during lung injury [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Present data support the role of Stat3 in enhancing epithelial cell survival and surfactant lipid synthesis that contribute to the maintenance of lung function. Deletion of <italic>Stat3 </italic>from type II alveolar epithelial cells induced the expression of the genes regulating protein metabolism, protein transport, chemotaxis and apoptosis while decreasing the expression of genes regulating lipid synthesis and metabolism. Critical to pulmonary function during injury, Stat3 influences the expression of genes regulating surfactant lipid synthesis and surfactant homeostasis including Abca3. As illustrated in Figure <xref ref-type="fig" rid="F4">4</xref>, the present study identified a complex regulatory network by which <italic>Stat3 </italic>regulates gene expression in type II alveolar cells that is required for cellular homeostasis following injury. STAT3 likely interacts with AKT/FOXA2 in the regulation a number of biological processes in alveolar type II cells, including cell survival/apoptosis, cholesterol and fatty acid biosynthesis required for surfactant homeostasis and lung function.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Schematic representation of the proposed role of Stat3 in cytoprotection of the lung in normal (A) versus <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice (B)</bold>. Stat3 plays critical role in cyto-protection during lung injury [12, 13]. Present data support the role of Stat3 in enhancing epithelial cell survival and surfactant lipid synthesis that contribute to the maintenance of lung function. For simplicity, only representative genes were included.</p></caption><graphic xlink:href="1471-2164-8-455-4"/></fig></sec><sec sec-type="methods"><title>Methods</title><sec><title>Transgenic Mice</title><p><italic>SP-C-rtTA/(tetO)7CMV-Cre</italic>/<italic>Stat3</italic><sup>flx/flx </sup>triple-transgenic mice were generated as described previously [<xref ref-type="bibr" rid="B12">12</xref>]. <italic>Stat3</italic>flx/flx mice were a kind gift of Dr. Takeda (Hyogo College of Medicine, Japan) [<xref ref-type="bibr" rid="B8">8</xref>]. In the presence of doxycycline, exon 21 of the <italic>Stat3 </italic>gene is permanently deleted from respiratory epithelial cells prior to birth (<italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice) [<xref ref-type="bibr" rid="B12">12</xref>]. <italic>Stat3 </italic>deleted transgenic (<italic>Stat3</italic><sup>&#x00394;/&#x00394;</sup>) and non-deleted littermates (double transgenic,<italic>SP-C-rtTA, or tetO7CMV-Cre </italic>and <italic>Stat3</italic><sup>flx/flx</sup>) were used for the experiments. Doxycycline was administered to the dams in the food at a concentration of 625 mg/kg (Harlan Teklad, Madison, WI) from embryonic day 0 (E0) to postnatal day 25 (P25), resulting in extensive deletion of <italic>Stat3 </italic>in respiratory epithelial cells [<xref ref-type="bibr" rid="B12">12</xref>]. As previously described, deletion of <italic>Stat3 </italic>did not alter lung size, morphology or survival under non-stressed condition [<xref ref-type="bibr" rid="B13">13</xref>].</p></sec><sec><title>RNA Extraction</title><p>Alveolar type II cells were isolated from 8 weeks old, sex and age matched littermate control and <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice using collagenase and differential plating as described by Rice <italic>et al.</italic>[<xref ref-type="bibr" rid="B77">77</xref>]. Type II cells from 3 mice were pooled to obtain one cell pellet. Three independent pools were generated from control and <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice separately for purification of RNA and microarray hybridization. Type II cells were homogenized with TRIzol reagent (Invitrogen, Carlsbad, CA). RNA concentration was measured by spectrophotometer and normalized prior to cDNA synthesis. These cell isolates consist of more than 90% alveolar type II cells with residual alveolar macrophages as the major contaminating cell. Purity was assessed by modified Papanicolaou stain. Purity and number of type II cells isolated from <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice were not different from controls.</p></sec><sec><title>RNA Microarray Analysis</title><p>mRNA was extracted from three independent pools of isolated type II cells from adult <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>and control mice. The cRNA was then hybridized to the murine genome MOE430 (consists of &#x02248; 45000 gene entries) chips (Affymetrix, Santa Clara, CA) according to the manufacturer's protocol. The RNA quality and quantity assessment, probe preparation, labeling, hybridization and image scan were carried out in the CCHMC Affymetrix Core using standard procedure. RNA quality and quantity were analyzed by spectrophotometer. The A260/A280 ratio was used to determine RNA purity with the acceptable region of 1.9&#x02013;2.1. Affymetrix Microarray Suite 5.0 was used to scan and quantitate the gene chips under default scan settings. Normalization was performed using the Robust Multichip Average model [<xref ref-type="bibr" rid="B78">78</xref>,<xref ref-type="bibr" rid="B79">79</xref>]. Data were further analyzed using affylmGUI from R/Bioconductor package [<xref ref-type="bibr" rid="B80">80</xref>]. Differentially expressed genes were selected with the threshold of T-Test P-value &#x02264; 0.05, False Discovery Rate (FDR) &#x02264; 10% and fold change &#x02265; 1.5. We prioritized the mRNAs whose abundance consistently changed in multiple probe sets by selecting them without the FDR consideration. Unknown cDNA clones/ESTs and duplicated gene entries were removed from further functional analysis.</p></sec><sec><title>Gene Ontology Analysis</title><p>Gene Ontology Analysis was performed using public available web-based tool David (database for annotation, visualization, and integrated discovery) [<xref ref-type="bibr" rid="B81">81</xref>]. Overrepresented biological processes were selected at the threshold of Fisher Exact Test P-Value &#x02264; 0.05 and minimum gene counts belonging to an annotation term &#x02265; 2%.</p></sec><sec><title>Promoter Analysis: Transcription Factor Binding Sites Search</title><p>Promoter sequences of all differentially expressed genes (-2000 bp upstream from the tentative TSS) were retrieved from our database (originally downloaded from UCSC Genome browser) and searched for over-represented TFBS (Transcription Factor Binding Site) in these sequences using MatInspector (Genomatix) using the complete Vertebrate Matrix Library 6.2. The P value is calculated using binomial distribution probability by comparing the matrix match of the promoter regions of differentially expressed genes with the promoters from random mouse genes sets (-2kb for all the promoters). The single-step Bonferroni adjustment is used to control for the multiple comparison effect (i.e., multiplication of p-value by the number of TFBS in Genomatix Vertebrate Matrix Library).</p></sec><sec><title>Pathway Enrichment Test</title><p>Overrepresented pathways were identified by comparison the overlap of differentially expressed genes and all genes in MOE430 mouse genome (reference) with the known KEGG pathways. A Fisher's exact test for 2&#x000b7;2 contingency table was used to calculate the statistical significance. A pathway is considered to be over-represented when a probability P value = 0.01 and gene frequency (genes in the pathway/total number of differentially expressed genes) &#x02265; 2%.</p></sec><sec><title>Literature Mining</title><p>Potential protein-protein or protein-DNA interactions were identified using Pathway Studio (Ariadne Genomics) that contains MedScan, an automated text-mining tool to search the entire PubMed and other public sources (The current version database contains more than 15 million Medline abstracts/full text). Gene expression profiling results was imported into the Studio and used to interpret pathways, gene regulation networks, and protein interaction maps.</p></sec><sec><title>Validation of mRNAs</title><p>Real-time RT-PCR was used to cross validate changes in a subset of genes from microarray selection. mRNA was extracted from alveolar type II epithelial cells isolated from <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>and control mice using RNeasy Protect mini kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. RNA concentration was measured by spectrophotometer. cDNA was made with SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, CA). <italic>Malt1, Rtn4, Reg3g, Bcl2l1, Abca3, Scap, Fasn, Srebf1 and Srebf2 </italic>were detected using primers listed Changes in mRNA were determined in type II cells isolated from <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>and controls (<italic>n </italic>= 3&#x02013;4/group). The following primers were used: <italic>Malt1</italic>: forward, TAT CCA GGA GGA CCC CAT GT and reverse, TCT GAT CAA AGC CAG TTA GCA TCAT; Rtn4: forward, AAG TGG AAG GAG TTT GAG AGA GCA and reverse, CTG TCT CAA AGC AGA TGT GAA AGC; <italic>Reg3g</italic>: forward, TGC CAA AAG AGC CCT CAG GA and reverse, TGC CTG AGG AAG AGG AAG GAT TCG; <italic>Bcl2l1</italic>: forward, TCT CTC TCC TCT GTC CAC CCT TG and reverse, TGC CCC TCA GAA GCC AGA AC; <italic>Abca3</italic>: forward, GCA TTG CCC TCA TTG GAG AGC CTG and reverse, TCC GGC CAT CCT CAG TGG TGG G; <italic>Scap</italic>: forward, TGA CCA CAA ACA AGG AGA GC and reverse, CAG GAA CAC CAA ACA GCA AG; <italic>Srebf1</italic>: forward, AAG CCG GGT GGG CGC CGG CGC CAT and reverse, GTC GTT CAA AAC CGC TGT GTC CAG; <italic>Srebf2</italic>: forward, CAT CCA GCA GCC TTT GAT ATA CCA G and reverse, AGG ACC GGG ACC TGC TGC ACC TGT G. <italic>Fasn</italic>: forward, GGA CAT GGT CAC AGA CGA TGA C and reverse, GTC GAA CTT GGA CAG ATC CTT CA. The PCR product was separated by the 1% agarose gel electrophoresis. &#x003b2;-actin was used as the internal control. Taqman Gene Expression Assay were used to confirm the expression of <italic>Akt2, Cdipt, Acox2, Cds2 and Gpam </italic>using Applied Biosystems 7300 Real-Time PCR System and company designed probes (Applied Biosystems). Statistical differences were determined using unpaired Student's t-tests.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Genes Differentially Expressed in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>Mice</bold>. Additional file descriptions text (including details of how to view the file, if it is in a non-standard format).</p></caption><media xlink:href="1471-2164-8-455-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Differentially Expressed Genes In Jak-Stat, Insulin and Wnt Signaling Pathway</bold>. Pathways were downloaded from KEGG website [82]. Each rectangle represents one or multiple gene products. Genes up-regulated in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice are highlighted in red. Genes down-regulated in <italic>Stat3</italic><sup>&#x00394;/&#x00394; </sup>mice are highlighted in blue. Rectangle contains more than one gene products and changes expression in opposite directions are highlighted in yellow.</p></caption><media xlink:href="1471-2164-8-455-S2.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Ann Maher for secretarial assistance, Valerie Besnard for scientific discussion. We also thank Dr. K. Takeda (Hyogo College of Medicine) for the gift of Stat3flx/flx mice.</p><p>This work was supported by National Institutes of Health Grant HL61646 to M. Ikegami, Y. Xu and J.A. Whitsett.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Z</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Darnell</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6</article-title><source>Science</source><year>1994</year><volume>264</volume><fpage>95</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">8140422</pub-id><pub-id pub-id-type="doi">10.1126/science.8140422</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Decker</surname><given-names>T</given-names></name><name><surname>Kovarik</surname><given-names>P</given-names></name></person-group><article-title>Serine phosphorylation of STATs</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>2628</fpage><lpage>2637</lpage><pub-id pub-id-type="pmid">10851062</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1203481</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>STAT family of transcription factors in cytokine-mediated biological responses</article-title><source>Cytokine Growth Factor Rev</source><year>2000</year><volume>11</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">10817963</pub-id><pub-id pub-id-type="doi">10.1016/S1359-6101(00)00005-8</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>T</given-names></name><name><surname>Ishihara</surname><given-names>K</given-names></name><name><surname>Hibi</surname><given-names>M</given-names></name></person-group><article-title>Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>2548</fpage><lpage>2556</lpage><pub-id pub-id-type="pmid">10851053</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1203551</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>DE</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name></person-group><article-title>What does Stat3 do?</article-title><source>J Clin Invest</source><year>2002</year><volume>109</volume><fpage>1143</fpage><lpage>1148</lpage><pub-id pub-id-type="pmid">11994402</pub-id><pub-id pub-id-type="doi">10.1172/JCI200215650</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Liao</surname><given-names>X</given-names></name><name><surname>Agarwal</surname><given-names>MK</given-names></name><name><surname>Barnes</surname><given-names>L</given-names></name><name><surname>Auron</surname><given-names>PE</given-names></name><name><surname>Stark</surname><given-names>GR</given-names></name></person-group><article-title>Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB</article-title><source>Genes &#x00026; development</source><year>2007</year><volume>21</volume><fpage>1396</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">17510282</pub-id><pub-id pub-id-type="doi">10.1101/gad.1553707</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inghirami</surname><given-names>G</given-names></name><name><surname>Chiarle</surname><given-names>R</given-names></name><name><surname>Simmons</surname><given-names>WJ</given-names></name><name><surname>Piva</surname><given-names>R</given-names></name><name><surname>Schlessinger</surname><given-names>K</given-names></name><name><surname>Levy</surname><given-names>DE</given-names></name></person-group><article-title>New and old functions of STAT3: a pivotal target for individualized treatment of cancer</article-title><source>Cell Cycle</source><year>2005</year><volume>4</volume><fpage>1131</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">16082218</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leeman</surname><given-names>RJ</given-names></name><name><surname>Lui</surname><given-names>VW</given-names></name><name><surname>Grandis</surname><given-names>JR</given-names></name></person-group><article-title>STAT3 as a therapeutic target in head and neck cancer</article-title><source>Expert Opin Biol Ther</source><year>2006</year><volume>6</volume><fpage>231</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">16503733</pub-id><pub-id pub-id-type="doi">10.1517/14712598.6.3.231</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>3801</fpage><lpage>3804</lpage><pub-id pub-id-type="pmid">9108058</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.8.3801</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacoby</surname><given-names>JJ</given-names></name><name><surname>Kalinowski</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>MG</given-names></name><name><surname>Zhang</surname><given-names>SS</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Chai</surname><given-names>GX</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>E</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>12929</fpage><lpage>12934</lpage><pub-id pub-id-type="pmid">14566054</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2134694100</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>W</given-names></name><name><surname>Ozaki</surname><given-names>M</given-names></name><name><surname>Haga</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Furukawa</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>N</given-names></name><name><surname>Kido</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Sakaue</surname><given-names>H</given-names></name><name><surname>Teshigawara</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Iguchi</surname><given-names>H</given-names></name><name><surname>Hiramatsu</surname><given-names>R</given-names></name><name><surname>LeRoith</surname><given-names>D</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Kasuga</surname><given-names>M</given-names></name></person-group><article-title>Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">14716305</pub-id><pub-id pub-id-type="doi">10.1038/nm980</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hokuto</surname><given-names>I</given-names></name><name><surname>Ikegami</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Perl</surname><given-names>AK</given-names></name><name><surname>Hull</surname><given-names>WM</given-names></name><name><surname>Wert</surname><given-names>SE</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name></person-group><article-title>Stat-3 is required for pulmonary homeostasis during hyperoxia</article-title><source>J Clin Invest</source><year>2004</year><volume>113</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">14702106</pub-id><pub-id pub-id-type="doi">10.1172/JCI200419491</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ikegami</surname><given-names>M</given-names></name><name><surname>Besnard</surname><given-names>V</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Hull</surname><given-names>WM</given-names></name><name><surname>Wert</surname><given-names>SE</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name></person-group><article-title>Stat3 is required for cytoprotection of the respiratory epithelium during adenoviral infection</article-title><source>J Immunol</source><year>2006</year><volume>177</volume><fpage>527</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">16785550</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Hossain</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Shipley</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Senior</surname><given-names>RM</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>C</given-names></name></person-group><article-title>Overexpression of Stat3C in pulmonary epithelium protects against hyperoxic lung injury</article-title><source>J Immunol</source><year>2005</year><volume>174</volume><fpage>7250</fpage><lpage>7256</lpage><pub-id pub-id-type="pmid">15905571</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>RS</given-names></name><name><surname>Lourenco</surname><given-names>PC</given-names></name><name><surname>Tonner</surname><given-names>E</given-names></name><name><surname>Flint</surname><given-names>DJ</given-names></name><name><surname>Selbert</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Clarke</surname><given-names>AR</given-names></name><name><surname>Watson</surname><given-names>CJ</given-names></name></person-group><article-title>Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>2604</fpage><lpage>2616</lpage><pub-id pub-id-type="pmid">10521404</pub-id><pub-id pub-id-type="doi">10.1101/gad.13.19.2604</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>DC</given-names></name><name><surname>Lin</surname><given-names>BH</given-names></name><name><surname>Lim</surname><given-names>CP</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Poli</surname><given-names>V</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><article-title>Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin</article-title><source>J Cell Biol</source><year>2006</year><volume>172</volume><fpage>245</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">16401721</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200503021</pub-id></citation></ref><ref id="B17"><citation citation-type="other"><article-title>Gene Expression Omnibus (GEO) Main Page</article-title><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/"/></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cantwell</surname><given-names>CA</given-names></name><name><surname>Sterneck</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>PF</given-names></name></person-group><article-title>Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1</article-title><source>Mol Cell Biol</source><year>1998</year><volume>18</volume><fpage>2108</fpage><lpage>2117</lpage><pub-id pub-id-type="pmid">9528783</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Elsner</surname><given-names>T</given-names></name><name><surname>Botella</surname><given-names>LM</given-names></name><name><surname>Velasco</surname><given-names>B</given-names></name><name><surname>Corbi</surname><given-names>A</given-names></name><name><surname>Attisano</surname><given-names>L</given-names></name><name><surname>Bernabeu</surname><given-names>C</given-names></name></person-group><article-title>Synergistic Cooperation between Hypoxia and Transforming Growth Factor-beta Pathways on Human Vascular Endothelial Growth Factor Gene Expression</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>38527</fpage><lpage>38535</lpage><pub-id pub-id-type="pmid">11486006</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M104536200</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Elsner</surname><given-names>T</given-names></name><name><surname>Ramirez</surname><given-names>JR</given-names></name><name><surname>Sanz-Rodriguez</surname><given-names>F</given-names></name><name><surname>Varela</surname><given-names>E</given-names></name><name><surname>Bernabeu</surname><given-names>C</given-names></name><name><surname>Botella</surname><given-names>LM</given-names></name></person-group><article-title>A cross-talk between hypoxia and TGF-beta orchestrates erythropoietin gene regulation through SP1 and Smads</article-title><source>J Mol Biol</source><year>2004</year><volume>336</volume><fpage>9</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">14741200</pub-id><pub-id pub-id-type="doi">10.1016/j.jmb.2003.12.023</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karlseder</surname><given-names>J</given-names></name><name><surname>Rotheneder</surname><given-names>H</given-names></name><name><surname>Wintersberger</surname><given-names>E</given-names></name></person-group><article-title>Interaction of Sp1 with the growth- and cell cycle-regulated transcription factor E2F</article-title><source>Mol Cell Biol</source><year>1996</year><volume>16</volume><fpage>1659</fpage><lpage>1667</lpage><pub-id pub-id-type="pmid">8657141</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanjay</surname><given-names>A</given-names></name><name><surname>Horne</surname><given-names>WC</given-names></name><name><surname>Baron</surname><given-names>R</given-names></name></person-group><article-title>The Cbl family: ubiquitin ligases regulating signaling by tyrosine kinases</article-title><source>Sci STKE</source><year>2001</year><volume>2001</volume><fpage>PE40</fpage><pub-id pub-id-type="pmid">11724969</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dinudom</surname><given-names>A</given-names></name><name><surname>Harvey</surname><given-names>KF</given-names></name><name><surname>Komwatana</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>JA</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Cook</surname><given-names>DI</given-names></name></person-group><article-title>Nedd4 mediates control of an epithelial Na+ channel in salivary duct cells by cytosolic Na+</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>7169</fpage><lpage>7173</lpage><pub-id pub-id-type="pmid">9618557</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.12.7169</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name></person-group><article-title>Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells</article-title><source>Nat Immunol</source><year>2001</year><volume>2</volume><fpage>870</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">11526404</pub-id><pub-id pub-id-type="doi">10.1038/ni0901-870</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YC</given-names></name><name><surname>Altman</surname><given-names>A</given-names></name></person-group><article-title>Cbl: complex formation and functional implications</article-title><source>Cell Signal</source><year>1998</year><volume>10</volume><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">9720760</pub-id><pub-id pub-id-type="doi">10.1016/S0898-6568(97)00179-4</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deckert</surname><given-names>M</given-names></name><name><surname>Elly</surname><given-names>C</given-names></name><name><surname>Altman</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name></person-group><article-title>Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn and Syk tyrosine kinases</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>8867</fpage><lpage>8874</lpage><pub-id pub-id-type="pmid">9535867</pub-id><pub-id pub-id-type="doi">10.1074/jbc.273.15.8867</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>DeYoung</surname><given-names>SM</given-names></name><name><surname>Hwang</surname><given-names>JB</given-names></name><name><surname>O'Leary</surname><given-names>EE</given-names></name><name><surname>Saltiel</surname><given-names>AR</given-names></name></person-group><article-title>The roles of Cbl-b and c-Cbl in insulin-stimulated glucose transport</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>36754</fpage><lpage>36762</lpage><pub-id pub-id-type="pmid">12842890</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M300664200</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magnifico</surname><given-names>A</given-names></name><name><surname>Ettenberg</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Mariano</surname><given-names>J</given-names></name><name><surname>Tiwari</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Lipkowitz</surname><given-names>S</given-names></name><name><surname>Weissman</surname><given-names>AM</given-names></name></person-group><article-title>WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>43169</fpage><lpage>43177</lpage><pub-id pub-id-type="pmid">12907674</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M308009200</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ungureanu</surname><given-names>D</given-names></name><name><surname>Silvennoinen</surname><given-names>O</given-names></name></person-group><article-title>SLIM trims STATs: ubiquitin E3 ligases provide insights for specificity in the regulation of cytokine signaling</article-title><source>Sci STKE</source><year>2005</year><volume>2005</volume><fpage>pe49</fpage><pub-id pub-id-type="pmid">16204702</pub-id><pub-id pub-id-type="doi">10.1126/stke.3042005pe49</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Drean</surname><given-names>Y</given-names></name><name><surname>Mincheneau</surname><given-names>N</given-names></name><name><surname>Le Goff</surname><given-names>P</given-names></name><name><surname>Michel</surname><given-names>D</given-names></name></person-group><article-title>Potentiation of glucocorticoid receptor transcriptional activity by sumoylation</article-title><source>Endocrinology</source><year>2002</year><volume>143</volume><fpage>3482</fpage><lpage>3489</lpage><pub-id pub-id-type="pmid">12193561</pub-id><pub-id pub-id-type="doi">10.1210/en.2002-220135</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>PC</given-names></name><name><surname>Behrmann</surname><given-names>I</given-names></name><name><surname>Muller-Newen</surname><given-names>G</given-names></name><name><surname>Schaper</surname><given-names>F</given-names></name><name><surname>Graeve</surname><given-names>L</given-names></name></person-group><article-title>Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway</article-title><source>Biochem J</source><year>1998</year><volume>334</volume><fpage>297</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">9716487</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>R</given-names></name><name><surname>Ochiai</surname><given-names>W</given-names></name><name><surname>Nakashima</surname><given-names>K</given-names></name><name><surname>Taga</surname><given-names>T</given-names></name></person-group><article-title>A new expression cloning strategy for isolation of substrate-specific kinases by using phosphorylation site-specific antibody</article-title><source>J Immunol Methods</source><year>2001</year><volume>247</volume><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">11150545</pub-id><pub-id pub-id-type="doi">10.1016/S0022-1759(00)00313-6</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cho</surname><given-names>YY</given-names></name><name><surname>Petersen</surname><given-names>BL</given-names></name><name><surname>Bode</surname><given-names>AM</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name></person-group><article-title>Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>12650</fpage><lpage>12659</lpage><pub-id pub-id-type="pmid">12562765</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M210368200</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>ZL</given-names></name><name><surname>Guan</surname><given-names>YJ</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Kane</surname><given-names>AB</given-names></name><name><surname>Chin</surname><given-names>YE</given-names></name></person-group><article-title>Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><fpage>9390</fpage><lpage>9400</lpage><pub-id pub-id-type="pmid">15485908</pub-id><pub-id pub-id-type="doi">10.1128/MCB.24.21.9390-9400.2004</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>RK</given-names></name><name><surname>Wise</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>YH</given-names></name></person-group><article-title>Prostacyclin receptor induces STAT1 and STAT3 phosphorylations in human erythroleukemia cells: a mechanism requiring PTX-insensitive G proteins, ERK and JNK</article-title><source>Cell Signal</source><year>2006</year><volume>18</volume><fpage>307</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">15979846</pub-id><pub-id pub-id-type="doi">10.1016/j.cellsig.2005.05.001</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loeffler</surname><given-names>B</given-names></name><name><surname>Heeren</surname><given-names>J</given-names></name><name><surname>Blaeser</surname><given-names>M</given-names></name><name><surname>Radner</surname><given-names>H</given-names></name><name><surname>Kayser</surname><given-names>D</given-names></name><name><surname>Aydin</surname><given-names>B</given-names></name><name><surname>Merkel</surname><given-names>M</given-names></name></person-group><article-title>Lipoprotein lipase facilitated uptake of LDL is mediated by the LDL receptor</article-title><source>J Lipid Res</source><year>2006</year><pub-id pub-id-type="pmid">17090659</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitsett</surname><given-names>JA</given-names></name></person-group><article-title>Genetic disorders of surfactant homeostasis</article-title><source>Paediatr Respir Rev</source><year>2006</year><volume>7</volume><fpage>S240</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">16798578</pub-id><pub-id pub-id-type="doi">10.1016/j.prrv.2006.04.191</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>ML</given-names></name><name><surname>Xavier</surname><given-names>R</given-names></name><name><surname>Haley</surname><given-names>KJ</given-names></name><name><surname>Welti</surname><given-names>R</given-names></name><name><surname>Goss</surname><given-names>JL</given-names></name><name><surname>Brown</surname><given-names>CE</given-names></name><name><surname>Zhuang</surname><given-names>DZ</given-names></name><name><surname>Bell</surname><given-names>SA</given-names></name><name><surname>Lu</surname><given-names>N</given-names></name><name><surname>McKee</surname><given-names>M</given-names></name><name><surname>Seed</surname><given-names>B</given-names></name><name><surname>Freeman</surname><given-names>MW</given-names></name></person-group><article-title>ABCA3 inactivation in mice causes respiratory failure, loss of pulmonary surfactant, and depletion of lung phosphatidylglycerol</article-title><source>J Lipid Res</source><year>2007</year><volume>48</volume><fpage>621</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">17142808</pub-id><pub-id pub-id-type="doi">10.1194/jlr.M600449-JLR200</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>ML</given-names></name><name><surname>Morris</surname><given-names>AL</given-names></name><name><surname>Chroni</surname><given-names>A</given-names></name><name><surname>Mendez</surname><given-names>AJ</given-names></name><name><surname>Zannis</surname><given-names>VI</given-names></name><name><surname>Freeman</surname><given-names>MW</given-names></name></person-group><article-title>ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux</article-title><source>J Lipid Res</source><year>2004</year><volume>45</volume><fpage>287</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">14617740</pub-id><pub-id pub-id-type="doi">10.1194/jlr.M300355-JLR200</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Silver</surname><given-names>DL</given-names></name><name><surname>Costet</surname><given-names>P</given-names></name><name><surname>Tall</surname><given-names>AR</given-names></name></person-group><article-title>Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>33053</fpage><lpage>33058</lpage><pub-id pub-id-type="pmid">10918065</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M005438200</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kather</surname><given-names>H</given-names></name></person-group><article-title>Pathways of purine metabolism in human adipocytes. Further evidence against a role of adenosine as an endogenous regulator of human fat cell function</article-title><source>J Biol Chem</source><year>1990</year><volume>265</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">2294125</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boison</surname><given-names>D</given-names></name><name><surname>Scheurer</surname><given-names>L</given-names></name><name><surname>Zumsteg</surname><given-names>V</given-names></name><name><surname>Rulicke</surname><given-names>T</given-names></name><name><surname>Litynski</surname><given-names>P</given-names></name><name><surname>Fowler</surname><given-names>B</given-names></name><name><surname>Brandner</surname><given-names>S</given-names></name><name><surname>Mohler</surname><given-names>H</given-names></name></person-group><article-title>Neonatal hepatic steatosis by disruption of the adenosine kinase gene</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>6985</fpage><lpage>6990</lpage><pub-id pub-id-type="pmid">11997462</pub-id><pub-id pub-id-type="doi">10.1073/pnas.092642899</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>JD</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name></person-group><article-title>SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver</article-title><source>J Clin Invest</source><year>2002</year><volume>109</volume><fpage>1125</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">11994399</pub-id><pub-id pub-id-type="doi">10.1172/JCI200215593</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Korn</surname><given-names>BS</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>Moon</surname><given-names>YA</given-names></name><name><surname>Komuro</surname><given-names>R</given-names></name><name><surname>Horton</surname><given-names>JD</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name></person-group><article-title>SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation</article-title><source>Genes Dev</source><year>2001</year><volume>15</volume><fpage>1206</fpage><lpage>1216</lpage><pub-id pub-id-type="pmid">11358865</pub-id><pub-id pub-id-type="doi">10.1101/gad.891301</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Tarr</surname><given-names>PT</given-names></name><name><surname>Wu</surname><given-names>PH</given-names></name><name><surname>Handschin</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Pei</surname><given-names>L</given-names></name><name><surname>Uldry</surname><given-names>M</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Newgard</surname><given-names>CB</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP</article-title><source>Cell</source><year>2005</year><volume>120</volume><fpage>261</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">15680331</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2004.11.043</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kaneko</surname><given-names>S</given-names></name><name><surname>Szewczyk</surname><given-names>KM</given-names></name><name><surname>Nicosia</surname><given-names>SV</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>JQ</given-names></name></person-group><article-title>Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>38932</fpage><lpage>38941</lpage><pub-id pub-id-type="pmid">16174774</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M504011200</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Briggs</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Niu</surname><given-names>G</given-names></name><name><surname>Kortylewski</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Gritsko</surname><given-names>T</given-names></name><name><surname>Turkson</surname><given-names>J</given-names></name><name><surname>Kay</surname><given-names>H</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Cheng</surname><given-names>JQ</given-names></name><name><surname>Jove</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name></person-group><article-title>Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>5552</fpage><lpage>5560</lpage><pub-id pub-id-type="pmid">16007214</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1208719</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barre</surname><given-names>B</given-names></name><name><surname>Avril</surname><given-names>S</given-names></name><name><surname>Coqueret</surname><given-names>O</given-names></name></person-group><article-title>Opposite regulation of myc and p21waf1 transcription by STAT3 proteins</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>2990</fpage><lpage>2996</lpage><pub-id pub-id-type="pmid">12438313</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M210422200</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porstmann</surname><given-names>T</given-names></name><name><surname>Griffiths</surname><given-names>B</given-names></name><name><surname>Chung</surname><given-names>YL</given-names></name><name><surname>Delpuech</surname><given-names>O</given-names></name><name><surname>Griffiths</surname><given-names>JR</given-names></name><name><surname>Downward</surname><given-names>J</given-names></name><name><surname>Schulze</surname><given-names>A</given-names></name></person-group><article-title>PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>6465</fpage><lpage>6481</lpage><pub-id pub-id-type="pmid">16007182</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abell</surname><given-names>K</given-names></name><name><surname>Watson</surname><given-names>CJ</given-names></name></person-group><article-title>The Jak/Stat pathway: a novel way to regulate PI3K activity</article-title><source>Cell Cycle</source><year>2005</year><volume>4</volume><fpage>897</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">15970662</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abell</surname><given-names>K</given-names></name><name><surname>Bilancio</surname><given-names>A</given-names></name><name><surname>Clarkson</surname><given-names>RW</given-names></name><name><surname>Tiffen</surname><given-names>PG</given-names></name><name><surname>Altaparmakov</surname><given-names>AI</given-names></name><name><surname>Burdon</surname><given-names>TG</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Vanhaesebroeck</surname><given-names>B</given-names></name><name><surname>Watson</surname><given-names>CJ</given-names></name></person-group><article-title>Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition</article-title><source>Nat Cell Biol</source><year>2005</year><volume>7</volume><fpage>392</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">15793565</pub-id><pub-id pub-id-type="doi">10.1038/ncb1242</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>AM</given-names></name><name><surname>Lo</surname><given-names>RK</given-names></name><name><surname>Wong</surname><given-names>CS</given-names></name><name><surname>Morris</surname><given-names>C</given-names></name><name><surname>Wise</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>YH</given-names></name></person-group><article-title>Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>35812</fpage><lpage>35825</lpage><pub-id pub-id-type="pmid">17008315</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M605288200</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolfrum</surname><given-names>C</given-names></name><name><surname>Besser</surname><given-names>D</given-names></name><name><surname>Luca</surname><given-names>E</given-names></name><name><surname>Stoffel</surname><given-names>M</given-names></name></person-group><article-title>Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>11624</fpage><lpage>11629</lpage><pub-id pub-id-type="pmid">14500912</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1931483100</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolfrum</surname><given-names>C</given-names></name><name><surname>Asilmaz</surname><given-names>E</given-names></name><name><surname>Luca</surname><given-names>E</given-names></name><name><surname>Friedman</surname><given-names>JM</given-names></name><name><surname>Stoffel</surname><given-names>M</given-names></name></person-group><article-title>Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes</article-title><source>Nature</source><year>2004</year><volume>432</volume><fpage>1027</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">15616563</pub-id><pub-id pub-id-type="doi">10.1038/nature03047</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ikegami</surname><given-names>M</given-names></name><name><surname>Stahlman</surname><given-names>MT</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Ang</surname><given-names>SL</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name></person-group><article-title>Foxa2 is required for transition to air breathing at birth</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>14449</fpage><lpage>14454</lpage><pub-id pub-id-type="pmid">15452354</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0404424101</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruefli-Brasse</surname><given-names>AA</given-names></name><name><surname>French</surname><given-names>DM</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><article-title>Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase</article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>1581</fpage><lpage>1584</lpage><pub-id pub-id-type="pmid">14576442</pub-id><pub-id pub-id-type="doi">10.1126/science.1090769</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wegener</surname><given-names>E</given-names></name><name><surname>Oeckinghaus</surname><given-names>A</given-names></name><name><surname>Papadopoulou</surname><given-names>N</given-names></name><name><surname>Lavitas</surname><given-names>L</given-names></name><name><surname>Schmidt-Supprian</surname><given-names>M</given-names></name><name><surname>Ferch</surname><given-names>U</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name><name><surname>Ruland</surname><given-names>J</given-names></name><name><surname>Heissmeyer</surname><given-names>V</given-names></name><name><surname>Krappmann</surname><given-names>D</given-names></name></person-group><article-title>Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation</article-title><source>Mol Cell</source><year>2006</year><volume>23</volume><fpage>13</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16818229</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2006.05.027</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalwadi</surname><given-names>H</given-names></name><name><surname>Krysan</surname><given-names>K</given-names></name><name><surname>Heuze-Vourc'h</surname><given-names>N</given-names></name><name><surname>Dohadwala</surname><given-names>M</given-names></name><name><surname>Elashoff</surname><given-names>D</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Cacalano</surname><given-names>N</given-names></name><name><surname>Lichtenstein</surname><given-names>A</given-names></name><name><surname>Dubinett</surname><given-names>S</given-names></name></person-group><article-title>Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>7674</fpage><lpage>7682</lpage><pub-id pub-id-type="pmid">16278387</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1205</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Kirschenbaum</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Klausner</surname><given-names>A</given-names></name><name><surname>Preston</surname><given-names>C</given-names></name><name><surname>Holland</surname><given-names>JF</given-names></name><name><surname>Levine</surname><given-names>AC</given-names></name></person-group><article-title>Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway</article-title><source>Biochem Biophys Res Commun</source><year>2002</year><volume>290</volume><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">11779161</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.2001.6188</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>JY</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Desiderio</surname><given-names>S</given-names></name><name><surname>Nathans</surname><given-names>D</given-names></name></person-group><article-title>Synergistic activity of STAT3 and c-Jun at a specific array of DNA elements in the alpha 2-macroglobulin promoter</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>26421</fpage><lpage>26429</lpage><pub-id pub-id-type="pmid">11319221</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M009935200</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kordula</surname><given-names>T</given-names></name><name><surname>Travis</surname><given-names>J</given-names></name></person-group><article-title>The role of Stat and C/EBP transcription factors in the synergistic activation of rat serine protease inhibitor-3 gene by interleukin-6 and dexamethasone</article-title><source>Biochem J</source><year>1996</year><volume>313</volume><fpage>1019</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">8611141</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Hagood</surname><given-names>JS</given-names></name><name><surname>Fuentes</surname><given-names>NL</given-names></name><name><surname>Fuller</surname><given-names>GM</given-names></name></person-group><article-title>STAT3 acts as a co-activator of glucocorticoid receptor signaling</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>30607</fpage><lpage>30610</lpage><pub-id pub-id-type="pmid">9388192</pub-id><pub-id pub-id-type="doi">10.1074/jbc.272.49.30607</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Konishi</surname><given-names>H</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Harano</surname><given-names>T</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Masuda</surname><given-names>A</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Osada</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>Identification of frequent G(2) checkpoint impairment and a homozygous deletion of 14-3-3epsilon at 17p13.3 in small cell lung cancers</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>271</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">11782387</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kino</surname><given-names>T</given-names></name><name><surname>Souvatzoglou</surname><given-names>E</given-names></name><name><surname>De Martino</surname><given-names>MU</given-names></name><name><surname>Tsopanomihalu</surname><given-names>M</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Chrousos</surname><given-names>GP</given-names></name></person-group><article-title>Protein 14-3-3sigma interacts with and favors cytoplasmic subcellular localization of the glucocorticoid receptor, acting as a negative regulator of the glucocorticoid signaling pathway</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>25651</fpage><lpage>25656</lpage><pub-id pub-id-type="pmid">12730237</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M302818200</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bromberg</surname><given-names>JF</given-names></name><name><surname>Wrzeszczynska</surname><given-names>MH</given-names></name><name><surname>Devgan</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Pestell</surname><given-names>RG</given-names></name><name><surname>Albanese</surname><given-names>C</given-names></name><name><surname>Darnell</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>Stat3 as an oncogene</article-title><source>Cell</source><year>1999</year><volume>98</volume><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">10458605</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81959-5</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alas</surname><given-names>S</given-names></name><name><surname>Bonavida</surname><given-names>B</given-names></name></person-group><article-title>Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>5137</fpage><lpage>5144</lpage><pub-id pub-id-type="pmid">11431352</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>SR</given-names></name><name><surname>Brunet</surname><given-names>A</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name></person-group><article-title>Cellular survival: a play in three Akts</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>2905</fpage><lpage>2927</lpage><pub-id pub-id-type="pmid">10579998</pub-id><pub-id pub-id-type="doi">10.1101/gad.13.22.2905</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>RG</given-names></name><name><surname>Parsons</surname><given-names>M</given-names></name><name><surname>Bonnard</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>VS</given-names></name><name><surname>Yeh</surname><given-names>WC</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name><name><surname>Ohashi</surname><given-names>PS</given-names></name></person-group><article-title>Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo</article-title><source>J Exp Med</source><year>2000</year><volume>191</volume><fpage>1721</fpage><lpage>1734</lpage><pub-id pub-id-type="pmid">10811865</pub-id><pub-id pub-id-type="doi">10.1084/jem.191.10.1721</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Juin</surname><given-names>P</given-names></name><name><surname>Hueber</surname><given-names>AO</given-names></name><name><surname>Littlewood</surname><given-names>T</given-names></name><name><surname>Evan</surname><given-names>G</given-names></name></person-group><article-title>c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>1367</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">10364155</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kadoya</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Yukita</surname><given-names>A</given-names></name><name><surname>Fukui</surname><given-names>A</given-names></name><name><surname>Michiue</surname><given-names>T</given-names></name><name><surname>Asahara</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Asashima</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>A</given-names></name></person-group><article-title>Desumoylation activity of Axam, a novel Axin-binding protein, is involved in downregulation of beta-catenin</article-title><source>Mol Cell Biol</source><year>2002</year><volume>22</volume><fpage>3803</fpage><lpage>3819</lpage><pub-id pub-id-type="pmid">11997515</pub-id><pub-id pub-id-type="doi">10.1128/MCB.22.11.3803-3819.2002</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname><given-names>PW</given-names></name><name><surname>Alpin</surname><given-names>J</given-names></name><name><surname>Rise</surname><given-names>CE</given-names></name><name><surname>Wright</surname><given-names>M</given-names></name><name><surname>Kreider</surname><given-names>BL</given-names></name></person-group><article-title>In vitro selection and characterization of Bcl-X(L)-binding proteins from a mix of tissue-specific mRNA display libraries</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>20898</fpage><lpage>20906</lpage><pub-id pub-id-type="pmid">11283018</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M011641200</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uetsuki</surname><given-names>T</given-names></name><name><surname>Takemoto</surname><given-names>K</given-names></name><name><surname>Nishimura</surname><given-names>I</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Niinobe</surname><given-names>M</given-names></name><name><surname>Momoi</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>M</given-names></name><name><surname>Yoshikawa</surname><given-names>K</given-names></name></person-group><article-title>Activation of neuronal caspase-3 by intracellular accumulation of wild-type Alzheimer amyloid precursor protein</article-title><source>J Neurosci</source><year>1999</year><volume>19</volume><fpage>6955</fpage><lpage>6964</lpage><pub-id pub-id-type="pmid">10436052</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>I</given-names></name><name><surname>Uetsuki</surname><given-names>T</given-names></name><name><surname>Kuwako</surname><given-names>K</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Kawakami</surname><given-names>T</given-names></name><name><surname>Aimoto</surname><given-names>S</given-names></name><name><surname>Yoshikawa</surname><given-names>K</given-names></name></person-group><article-title>Cell death induced by a caspase-cleaved transmembrane fragment of the Alzheimer amyloid precursor protein</article-title><source>Cell Death Differ</source><year>2002</year><volume>9</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">11840170</pub-id><pub-id pub-id-type="doi">10.1038/sj/cdd/4400931</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>FL</given-names></name><name><surname>Denault</surname><given-names>JB</given-names></name><name><surname>Riedl</surname><given-names>SJ</given-names></name><name><surname>Shin</surname><given-names>H</given-names></name><name><surname>Renatus</surname><given-names>M</given-names></name><name><surname>Salvesen</surname><given-names>GS</given-names></name></person-group><article-title>XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs</article-title><source>Embo J</source><year>2005</year><volume>24</volume><fpage>645</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">15650747</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7600544</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>HB</given-names></name><name><surname>Halpin</surname><given-names>DR</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name></person-group><article-title>Casper is a FADD- and caspase-related inducer of apoptosis</article-title><source>Immunity</source><year>1997</year><volume>6</volume><fpage>751</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">9208847</pub-id><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80450-1</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruna</surname><given-names>A</given-names></name><name><surname>Nicolas</surname><given-names>M</given-names></name><name><surname>Munoz</surname><given-names>A</given-names></name><name><surname>Kyriakis</surname><given-names>JM</given-names></name><name><surname>Caelles</surname><given-names>C</given-names></name></person-group><article-title>Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids</article-title><source>Embo J</source><year>2003</year><volume>22</volume><fpage>6035</fpage><lpage>6044</lpage><pub-id pub-id-type="pmid">14609950</pub-id><pub-id pub-id-type="doi">10.1093/emboj/cdg590</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>WR</given-names></name><name><surname>Conkright</surname><given-names>JJ</given-names></name><name><surname>Na</surname><given-names>CL</given-names></name><name><surname>Ikegami</surname><given-names>M</given-names></name><name><surname>Shannon</surname><given-names>JM</given-names></name><name><surname>Weaver</surname><given-names>TE</given-names></name></person-group><article-title>Maintenance of the mouse type II cell phenotype in vitro</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2002</year><volume>283</volume><fpage>L256</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">12114186</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Hobbs</surname><given-names>B</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><name><surname>Beazer-Barclay</surname><given-names>YD</given-names></name><name><surname>Antonellis</surname><given-names>KJ</given-names></name><name><surname>Scherf</surname><given-names>U</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><article-title>Exploration, normalization, and summaries of high density oligonucleotide array probe level data</article-title><source>Biostatistics</source><year>2003</year><volume>4</volume><fpage>249</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">12925520</pub-id><pub-id pub-id-type="doi">10.1093/biostatistics/4.2.249</pub-id></citation></ref><ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Bolstad</surname><given-names>BM</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><name><surname>Cope</surname><given-names>LM</given-names></name><name><surname>Hobbs</surname><given-names>B</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><article-title>Summaries of Affymetrix GeneChip probe level data</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><fpage>e15</fpage><pub-id pub-id-type="pmid">12582260</pub-id><pub-id pub-id-type="doi">10.1093/nar/gng015</pub-id></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>Linear models and empirical bayes methods for assessing differential expression in microarray experiments</article-title><source>Statistical applications in genetics and molecular biology Bioconductor</source><year>2004</year><volume>3</volume><fpage>Article3</fpage><ext-link ext-link-type="uri" xlink:href="http://bioconductor.org/"/></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Hosack</surname><given-names>DA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><article-title>DAVID: Database for Annotation, Visualization, and Integrated Discovery</article-title><source>Genome Biol DAVID</source><year>2003</year><volume>4</volume><fpage>P3</fpage><ext-link ext-link-type="uri" xlink:href="http://david.abcc.ncifcrf.gov/home.jsp"/><pub-id pub-id-type="doi">10.1186/gb-2003-4-5-p3</pub-id></citation></ref><ref id="B82"><citation citation-type="other"><article-title>KEGG</article-title><ext-link ext-link-type="uri" xlink:href="http://www.genome.ad.jp/kegg/"/></citation></ref></ref-list></back></article> 